Document:

Supply and Distribution Agreement

 Exhibit 10.13 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

 SUPPLY AND DISTRIBUTION AGREEMENT 

This Supply and Distribution Agreement is entered on this 20th day of May, 2011 (the “Effective Date”)
between Mylan Pharmaceuticals Inc., a West Virginia corporation having its corporate offices at 781 Chestnut Ridge, Morgantown, West Virginia 26505, USA (“Mylan”); and Insys Therapeutics, Inc., a Delaware corporation having its corporate
offices at 10220 South 51st Street, Suite 2, Phoenix, AZ
85044 (“Insys”). 
 WHEREAS, Insys has developed the ANDA for the Product, as defined below, which it will have
manufactured under a separate contract by Catalent Pharma Solutions, Inc. (“Catalent”), a Third Party Manufacturer using Insys’ ANDA, and Insys desires to engage Mylan to distribute it; and 

WHEREAS, Mylan is willing to distribute the Product, as produced by Catalent for supply to Mylan and/or its Affiliates for sale in the
Territory, all in accordance with the terms and conditions of this Agreement. 
 NOW THEREFORE, intending to be legally bound
and in consideration of the mutual promises, covenants and conditions set forth herein, and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, Mylan and Insys agree as follows: 

ARTICLE 1 – DEFINITIONS 
 1.1 “Adverse Drug Experience” shall mean an adverse event associated with the use of the Product in humans, whether or not considered drug related, including the following: an adverse
event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug
withdrawal; and any failure of expected pharmacological action. The above definition of “Adverse Drug Experience” is intended to be synonymous with 21 C.F.R. § 314.80(a) and will be deemed to be changed to reflect any changes to that
section of the U.S. Code of Federal Regulations. 
 1.2 “Affiliate” shall mean any corporation, association,
partnership, company, organization, or other entity which directly or indirectly controls, is controlled by, or is under common control with Mylan or Insys as the case may be. For purposes of this definition, control means the ability, directly or
indirectly, through ownership of securities or other equity interests, by agreement, or by any other lawful method, to direct more than fifty percent (50%) of the outstanding equity votes of any entity, whether or not represented by securities,
or to otherwise control the management decisions of any entity. 
 1.3 “Agreement” shall mean this Supply and
Distribution Agreement. 

 1.4 “ANDA” shall mean an Abbreviated New Drug Application within the
meaning of Section 505(j) of the U.S. Food, Drug and Cosmetic Act. 
 1.5 “cGMPs” shall mean all laws and
regulations relating to the manufacture of the Product, including, without limitation, the current Good Manufacturing Practices as specified in the United States Code of Federal Regulations (the “CFR”) and any other applicable Laws,
guidelines and/or regulations. 
 1.6 “COA” shall have the meaning ascribed to it in Section 5.1.

 1.7 “COC” shall have the meaning ascribed to it in Section 5.1. 

1.8 “Commercially Reasonable Efforts” shall mean that degree of effort, expertise and resources which a person of
ordinary skill, ability and experience in the matters addressed in this Agreement would utilize and otherwise apply with respect to fulfilling the obligations assumed under this Agreement. 

1.9 “Competing Product” shall mean [...***...]. 

1.10 “Components” shall mean the Active Ingredients, excipients, and any other product or material used in the
manufacture of the Products including the packaging materials. 
 1.11 “DEA” shall mean the Drug Enforcement
Administration of the United States Department of Justice. 
 1.12 “FDA” shall mean the United States Food and
Drug Administration. 
 1.13 “Force Majeure” shall mean any circumstances reasonably beyond a Party’s
control including, without limitation, acts of God, civil disorders or commotions, acts of aggression, fire, explosions, floods, hurricanes, drought, war, sabotage, terrorism, embargo, utility failures, supplier failures, material shortages, labor
disturbances, strikes, a national emergency or appropriations of property. 
 1.14 “GAAP” means generally
accepted accounting principles, consistently applied. 
 1.15 “Indemnified Party” shall have the meaning
ascribed to it in Section 9.4. 
 1.16 “Indemnifying Party” shall have the meaning ascribed to it in
Section 9.4. 
 1.17 “Law” shall mean any rule, regulation, statute, ordinance or other rule of law,
including but not limited to cGMPs, relevant to the manufacture, distribution, storage, testing, shipping, marketing and/or sale of any or all of the Product(s), or to any other matters covered by this Agreement. 

1.18 “Legal Expenses” shall have the meaning ascribed to it in Section 8.2. 

1.19 “Losses” shall mean liabilities, damages, costs or expenses, including reasonable attorneys’ fees, incurred by
either Party which arise from any claim, lawsuit or other action by a Third Party. 

  
 ***Confidential
Treatment Requested    2 

 1.20 “Insys” shall mean Insys Therapeutics, Inc. and its Affiliates.

 1.21 “Manufacture” or “Manufacturing” shall mean the production of finished Product(s) in
accordance with applicable Specifications. 
 1.22 “MSDS” shall have the meaning ascribed to it in
Section 4.1. 
 1.23 “Mylan” shall mean Mylan Pharmaceuticals Inc. and its Affiliates. 

1.24 “Mylan Distribution and Storage Fee” shall mean Mylan’s applicable distribution and storage costs to get the
Product to market, and shall be [...***...]. 
 1.25 “Mylan Royalty” shall be equal to [...***...].

 1.26 “Net Sales” shall mean [...***...]. 

1.27 “Package” or “Packaging” shall mean packaging finished Drug Product(s) in accordance with applicable
Specifications, including, without limitation, executed batch records. 
 1.28 “Parties” shall mean Mylan and
Insys. 
 1.29 “Product” shall mean the Product set forth on Schedule A. 

1.30 “Product ANDA” shall mean the ANDA owned by Insys which has been issued by the FDA specifically for marketing the
Product in the Territory. 
 1.31 “Product Net Price” shall mean [...***...]. 

1.32 “Specifications” shall mean [...***...]. 

1.33 “Term of this Agreement” shall have the meaning ascribed to it in Section 11.1. 

1.34 “Territory” means [...***...]. 
 1.35 “Third Party” shall mean any entity or person other than Mylan or Insys. 
 1.36 “Third Party Manufacturer” shall mean Catalent Pharma Solutions, Inc., or any successor manufacturer of the Product acceptable to MYLAN under a written agreement between MYLAN and
Insys. 
 1.37 “Transfer Price” shall mean the transfer price for the Product, [...***...]. 

ARTICLE 2 – INSPECTION 
 2.1 Condition Precedent Facility Audit. As a pre-requisite to this Agreement, MYLAN may perform a quality audit of Insys’s, and/or its Third Party Manufacturer’s facilities, which
shall include the inspection of each physical plant and documentation (“Condition Precedent Facility Audit”). Mylan shall provide Insys a minimum of fourteen (14) calendar days 

  
 ***Confidential
Treatment Requested    3 

 
before any Condition Precedent Facility Audit. The Condition Precedent Facility Audit will have the purpose of verifying compliance with GMP rules and Mylan’s quality requirements.

 2.2 Negative Outcome of Condition Precedent Facility Audit. If the results of the Condition Precedent Facility
Audit are not, in the sole opinion of Mylan, satisfactory, Insys shall perform, at its own expense, the requested or appropriate modifications of its facilities or its Third Party Manufacturer’s facilities reasonably necessary to cure the
deficiencies identified during the Condition Precedent Facility Audit. Insys shall provide satisfactory evidence of these modifications to Mylan and Mylan shall be entitled to perform an additional Condition Precedent Facility Audit with prior
notice to ensure that the deficiencies identified during the Condition Precedent Facility Audit have been cured (“Additional Condition Precedent Facility Audit”). 
 2.2.1 The Parties agree and acknowledge that a satisfactory outcome of either the Condition Precedent Facility Audit or the additional Condition Precedent Facility Audit if applicable is a condition
precedent to the formation and validity of this Agreement. 
 2.3 Continuing Right to Audit. [...***...].
During such an inspection or audit the inspectors may inquire about the progress of the work being carried out by Insys or its Third Party Manufacturer, and are in particular but not exclusively authorized to:. 

 

	 	2.3.1	Inspect or audit the facilities, documents, cost records and equipment used in the manufacture, packaging, storage, shipping and quality control of the Product and the
Components; and 

  

	 	2.3.2	Verify the qualifications of the employees carrying out such work and their use of the relevant equipment; and 

 

	 	2.3.3	Evaluate all scientific techniques used by Insys or any Third Party Manufacturer’s employees in the execution of this Agreement and the procedures used in the
creation and storage of samples of the Product. 

  

	 	2.3.4	Verify and evaluate information relating to the utilization of the Manufacturing and Packaging capacity of Insys’s or its Third Party Manufacturer’s
facilities, including its physical plant, or its Third Party Manufacturer’s facilities including its physical plant. 

 2.4 Access. Insys agrees that it shall provide Mylan’s inspectors with unfettered access to all of the facilities and information related to all of the facilities, in order that
the inspectors may carry out the inspections or inquiries referred to in the provisions of this Article. 
 2.5
Corrective Action Plan. Insys on behalf of itself and its Third Party Manufacturer agrees that it shall use its best endeavors to ensure that within thirty (30) calendar days after receipt of an audit report signed by an authorized
representative of Mylan, Insys and/or its Third Party Manufacturer shall respond to the audit report with a written corrective action plan that includes a detailed timeline. Upon receipt of Mylan’s approval of the written corrective action
plan, Insys shall, or shall cause its Third Party Manufacturer to remediate any 

  
 ***Confidential
Treatment Requested    4 

 
and all discrepancies set forth in the audit report. The cost of such remediation shall be born by Insys or its Third Party Manufacturer. 

2.6 Supplier Audits. Insys is responsible for auditing the facilities of the suppliers of Components that are supplied to
the Third Party Manufacturer, and Insys agrees to provide Mylan, upon Mylan’s request with a current copy of the audit report of these facilities. 
 ARTICLE 3 – EXCLUSIVITY 
 3.1 Exclusive Supply. During the Term
of this Agreement and subject to the terms hereof, Insys will be fully responsible for supplying the Product [...***...]. 

3.2 No Sales Outside the Territory. During the Term of this Agreement, Mylan shall not promote or distribute the Product supplied
to Mylan under this Agreement by Insys outside the Territory, nor shall Mylan sell such Product to any purchaser that Mylan knows, or reasonably ought to know, intends to resell or redistribute the Product outside the Territory. For avoidance of
doubt, nothing in this Agreement shall preclude or limit Mylan from marketing, promoting, manufacturing, purchasing, packaging, re-packaging, distributing, or selling another product that contain the same active ingredients as the Product outside
the Territory. 
 3.3 Right of First Refusal For Other Territories. During the Term of this Agreement, if at any time
Insys desires to market the Product in any other territory in addition to the Territory as defined herein, Mylan shall have the right of first refusal to market the Product in the new territory or territories. [...***...]. 

ARTICLE 4 – SUPPLY 
 4.1 Production by Third Party Manufacturer. It is understood and agreed between Insys and Mylan that the Product shall be manufactured by a Third Party Manufacturer under a written agreement
between Insys and that Third Party Manufacturer. Insys shall at all times during the term hereof be responsible for the performance of the Third Party Manufacturer, and shall be responsible to Mylan for performance of all of the duties and
obligations hereunder which may actually be performed on behalf of Insys by said Third Party Manufacturer, including but not limited to, meeting the specifications, timely delivery, etc. 

4.2 Delivery and Risk of Loss. Insys shall make deliveries of Product(s) to Mylan’s [...***...] facility within the
period that is no more than [...***...] days before or [...***...] calendar days after Mylan’s specified delivery date. [...***...]. The terms and conditions of this Agreement shall be controlling over any conflicting terms
and conditions stated in Mylan’s purchase order or Insys’ invoice or confirmation. Any other document which shall conflict with or be in addition to the terms and conditions of this Agreement is hereby rejected, unless the Parties shall
have mutually agreed to the contrary in writing in respect of a particular instance. 
 4.3 Forecasts. [...***...].

 4.4 Conformance to Specifications. Insys will order the Product from a third party manufacturer for shipment to Mylan
in accordance with the Specifications set forth in the 

  
 ***Confidential
Treatment Requested    5 

 
ANDA, as such regulatory approval may be amended or supplemented from time to time, and applicable Law. Mylan shall be promptly and fully advised of any new instructions or Specifications
required by the FDA or by Law and the Parties shall confer with respect to the best mode of compliance with such requirements. 

4.5 Alternate Manufacture Site(s). Mylan shall have the right, at its own expense, to qualify one or more Mylan facilities as an
alternate site of manufacture for the Product set forth herein and for other products as may be later added to this Agreement by way of an addendum or amendment. Mylan may use such alternative site(s) for the actual manufacture of the Product only
if (i) Insys cannot supply Mylan’s requirements of the Product in accordance with Sections 4.1, 4.2, 4.7 and other applicable provisions herein (for reasons other than Insys’ inability to obtain adequate quota of API from the DEA to
supply the Third Party Manufacturer through no fault of Insys ), and (ii) Insys consents in writing to the use of each alternative site, which written consent shall not be unreasonably withheld. 

4.6 Active Pharmaceutical Ingredients. For the Product, Insys make certain that the Third Party Manufacturer uses Commercially
Reasonable Efforts to maintain a rotating inventory of the required active pharmaceutical ingredients (“API”) and inactive pharmaceutical ingredients (“IPI”) in sufficient quantities to satisfy binding purchase orders provided by
Mylan to Insys (the “API and IPI Rotating Inventory”). Insys will also make certain that the Third Party Manufacturer manages the API and IPI Rotating Inventory on a “First-In First-Out” (FIFO) basis, in accordance with cGMPs.
Insys, as the API supplier, shall perform an audit of its facility supplying the API, and shall certify the results to Mylan, and shall supply Mylan with a copy of the certified audit report within five (5) calendar days of its completion.
Insys shall be responsible for the performance of the Third Party Manufacturer under this Section 4.6, and shall provide reports regarding the regular and successful completion of all of these obligations regarding API to Mylan on a timely
basis. 
 4.7 Late Delivery and Failure to Supply. Upon failure by Insys to supply binding quantities of the Product(s)
within the time limits set forth in Section 4.2 above, Mylan may elect to manufacture for itself or purchase the amount of the shortfall from a third party for the period that Insys is unable to timely deliver the full amount of the quantities
set forth in then current and subsequent purchase orders. In such case, for the shortfall quantity as per the purchase orders, if Mylan chooses to manufacture the same itself or at a third party, Insys will reimburse Mylan the difference between the
Price of such undelivered Product(s) manufactured at Insys and the same Product manufactured at Mylan or by a third party. Insys will provide Mylan written notification when it is able to supply the Product(s) in accordance with Mylan’s
purchase orders, to enable Mylan to resume obtaining Product from Insys. However, Insys shall not be responsible for failure to supply the Product(s) at the agreed timeline if the same is due to the existence of Force Majeure conditions. For any
such failure to supply, Insys shall be liable for: (a) [...***...]; (b) the cost of delivery to Mylan by air freight, if required to meet Mylan’s commitments to its customers; and (c) any third party customer penalties
levied against Mylan arising from its failure to supply Product(s) in accordance with binding purchase orders, subject to receipt by Insys of appropriate evidence thereof. The rights of Mylan set forth in this Section 4.7 are in addition to any
other rights set forth in this Agreement. 

  
 ***Confidential
Treatment Requested    6 

 ARTICLE 5 – PRODUCT TESTING / INSPECTIONS 

5.1 Testing and Inspections. Insys shall make certain that the Third Party Manufacturer performs quality assurance testing with
respect to the Product, including stability testing, so that the Product conforms to the Specifications and applicable Law. Insys shall make certain that the Third Party Manufacturer provides the results thereof to Mylan in the form of a Certificate
of Analysis (“COA”) and a Certificate of Conformance (“COC”). Insys will also make certain that the Third Party Manufacturer provides Mylan with Material Safety Data Sheets (“MSDS”) as required for the Product, and
updates of the same as necessary. Insys will make certain that the Third Party Manufacturer arranges for Mylan’s personnel, upon reasonable notice, to visit for reasonable durations during regular business hours its facility or any other third
party manufacturer facility used for the manufacture, packaging, storage, testing or release of the Product, including to observe the manufacture, testing and release of the Product, and will arrange that such Mylan personnel may review and make
copies of any relevant records in connection therewith. Any deficiencies in cGMPs as practiced at any such facility and noted by Mylan during such inspection will be communicated to Insys and Insys will make certain that the Third Party Manufacturer
uses reasonable efforts to remediate such deficiencies. In the event that Insys or the Third Party Manufacturer disputes that such deficiencies relate to cGMPs, then Insys may refer the matter to the dispute resolution process provided by
Section 12.8 of this Agreement. Mylan’s right to inspect production facilities under this Section 5.1 shall be limited to one (1) inspection per calendar year, unless deficiencies in cGMPs are being remediated pursuant to the
immediately preceding sentence, in which case Mylan may conduct additional inspections upon reasonable notice until such deficiencies are remediated. Mylan agrees that it will not, directly or indirectly (through any other persons, entity or
otherwise) develop, manufacture, sell, or market, any generic pharmaceutical product which has the same active ingredients and strength as the Drug Product using the information provided in the Insys ANDA or other confidential information provided
to Mylan by Insys or by the Third Party Manufacturer pursuant to this paragraph. 
 5.2 Rejection of Non-Conforming Goods.
Mylan shall have a period of thirty (30) calendar days from the later of (a) the date of Mylan’s receipt of the Product at the designated Mylan facility, or (b) the date of Mylan’s receipt of the COAs and COCs applicable
to such Product, to inspect any shipment of Product to determine whether such Product conform to the Specifications. If Mylan determines that the Product does not conform to the Specifications, it shall immediately notify Insys. Mylan’s failure
to notify Insys of the non-conformity within the thirty (30) calendar day period specified above will be deemed for purposes of this Agreement as Mylan’s acceptance of such Product, and shall constitute a waiver of any claims Mylan may
have with respect to the non-conformity of such shipment to the Specifications, subject to Mylan’s right to reject Product for latent defects discovered by Mylan or Mylan’s customers after such period has expired. If Insys agrees that the
Product does not conform to the Specifications, Mylan shall return the non-conforming Product to Insys at a location designated by Insys and at Insys’ expense. Insys shall use Commercially Reasonable Efforts to replace any non-conforming
Product within the shortest possible time. Mylan shall have no responsibility to Insys for the amounts invoiced for the replacement Product, but shall pay Insys the applicable amounts for the original non-conforming Product. 

5.3 Disputes. [...***...]. 

  
 ***Confidential
Treatment Requested    7 

 ARTICLE 6 – REGULATORY RESPONSIBILITIES 

6.1 ANDA Holder’s Responsibilities. As the owner and holder of the ANDA, Insys shall be responsible for preparing and filing
the ANDA for the Product, and for any new temperature stable version which Insys may develop. Insys shall own the ANDA and shall perform all regulatory functions in accordance with applicable Law and requirements of the FDA, including the filing of
all annual and other reports or filings required by the FDA, and all other regulatory and governmental permits, licenses and approvals for the Product in accordance with the terms of this Agreement. Both the Parties will communicate with each other
with regard to any regulatory issues that may arise before or after the final approval. 
 6.2 NDC Codes. Mylan shall
obtain its own labeler code, drug listing and NDC for use in connection with the sale of Product. 
 6.3 Adverse Drug
Experiences. Unless otherwise set forth on Schedule B, attached hereto, and made a part hereof, Mylan shall have responsibility for all pharmacovigilance activities associated with the marketing and sale of the Product in the Territory.
Insys will submit to Mylan any and all reports of Adverse Drug Experiences that Insys or its third party manufacturer receives, together with all relevant information possessed by either within three (3) business days of receipt. Insys shall
also promptly submit to Mylan any product complaints for investigation within three (3) business days of receipt. Mylan shall acknowledge receipt of Insys-submitted Adverse Drug Experiences and product complaints within one (1) business
day of receipt. Each Party shall cooperate with the other and provide information in its possession to the extent necessary for the other Party to comply with all legal requirements relating to the manufacture or marketing of the Product in the
Territory. 
 6.4 Recalls. The Parties agree that the procedure for a Product recall and FDA notifications shall depend
on whether the issue arose from activities performed by Mylan or from activities performed by Insys. Only Mylan can initiate a recall. In the event of a product recall, Mylan shall provide all necessary lists; Insys shall be responsible for all FDA
contacts. In the event that the FDA or other governmental body orders a recall with respect to any Product supplied hereunder or a recall is voluntarily initiated by Mylan, and the cause of such recall is due to (a) a breach by Insys of any of
its representations, warranties, obligations, covenants or other agreements contained herein or in other written agreements between the Parties, then Insys shall be liable, and shall reimburse Mylan for the reasonable Losses, Legal Expenses and
other out-of-pocket costs and expenses relating to or arising out of such recall, or (b) a breach by Mylan of any of its representations, warranties, obligations, covenants or other agreements contained herein, then Mylan shall be liable and
shall reimburse Insys for its reasonable Losses, Legal Expenses and other out-of-pocket costs and expenses relating to or arising out of such recall; provided that if both parties share responsibility with respect to such recall, the costs shall be
shared in the ratio of the Parties’ contributory responsibility. Insys and Mylan agree to abide by all Healthcare Distribution Management Association published guidelines for product recall reimbursement. The Parties shall each maintain
traceability records as are sufficient and as may be necessary to permit a recall. The Parties agree that if either Party shall discover or become aware of any fact, condition, circumstance or event (whether actual or potential) concerning or
related to the Product which may reasonably require a recall, such Party shall promptly communicate such fact, condition, circumstance or event to the other Party. In the event (a) the FDA or other governmental body requests that the Product be
recalled or (b) a court of competent jurisdiction orders such a recall, the Parties shall take all appropriate remedial actions 

  
 8 

 
with respect to such recall. The obligations under this Section shall survive the complete or partial termination of this Agreement. Each Party shall make every reasonable effort to mitigate any
Losses, Legal Expenses and other out-of-pocket costs and expenses to be reimbursed by the other Party pursuant to this Section. 

6.5 Retention of Samples. The Parties shall keep such samples and records in respect of the Product as are required by applicable
Law for such period of time as may be required by Law. 
 6.6 FDA Correspondence. Each of Mylan and Insys shall promptly
inform the other of any correspondence from the FDA regarding the Product that would materially affect its ability to meet its obligations under this Agreement. Each of Mylan and Insys shall notify the other promptly of any materially adverse
inspections by the FDA or other regulatory authorities which pertain to the Product or to the facilities of such Party or its Affiliate where the Product are being manufactured or stored, or any occurrences or information that arise out of
Insys’ manufacturing activities that have or could reasonably be expected to have adverse regulatory compliance or reporting consequences concerning the Product or which might otherwise be reasonably expected to adversely affect the supply by
Insys of Product to Mylan. 
 6.7 Technical and Pharmacovigilance Agreements. Within ninety (90) calendar days
following mutual signature of this Agreement, if possible, the Parties shall enter into a Technical Agreement in form and content reasonably acceptable to the Parties and containing protocols and specific responsibilities for handling Product
quality complaints, in accordance with Mylan’s and/or Insys’ standard operating procedures and in conformity with applicable Law. A breach by a Party to the terms of the Technical Agreement shall be considered a breach of this Agreement.
The Pharmacovigilance responsibilities of the Parties are set forth in Section 6.3 above, and on Schedule B. Until such a Technical Agreement is entered into between the Parties, this Agreement in conjunction with all applicable
Regulatory Authority requirements, and Applicable Law shall govern the Parties’ responsibilities with respect to procedures impacting the identity, strength, quality and purity of the Product(s). 

6.8 Artwork and Packaging. Mylan shall provide or approve, prior to the procurement of applicable components, all artwork,
advertising and Packaging information necessary to process or Package the Product. Such artwork, advertising and Packaging is and shall remain the exclusive property of Mylan, and Mylan shall be solely responsible for the content thereof. Such
artwork, advertising and Packaging information or any reproduction thereof may not be used by Insys or by the Third Party Manufacturer following the termination of this Agreement, or during the Term of this Agreement in any manner other than solely
for the purpose of performing obligations pursuant to this Agreement. 
 6.9 Drug Enforcement Agency (“DEA”)
Requirements. Insys shall be responsible for and shall secure at its sole expense any required DEA API quota, clearances or permits. 

  
 9 

 ARTICLE 7 – TRANSFER PRICING, DISTRIBUTION FEE AND PROFIT DISTRIBUTION

 7.1 Transfer Pricing. The initial Transfer Price for the Product shall be as set forth on Schedule A.
[...***...]. 
 7.2 Transfer Pricing Invoicing. Insys shall invoice Mylan [...***...] each shipment at the
time of such shipment. Mylan will pay such invoices within [...***...] of receipt by Mylan of those orders received by Insys prior to commercial launch of the Product and for [...***...] after commercial launch of the Product. For all
orders of Product received more than [...***...] after commercial launch, Mylan will pay those invoices within [...***...] of receipt by Mylan of the orders. 
 7.3 Distribution and Storage Fee. Insys shall pay to Mylan a Distribution and Storage Fee in the amount of [...***...]. 

7.4 Mylan Deductions. Mylan shall deduct and retain: 
 (a) [...***...] 
 (b) [...***...]. 

7.5 Insys Revenue. Insys Revenue is defined as [...***...]. Insys Revenue will be determined on a calendar quarterly
basis and shall be paid by Mylan to Insys within thirty (30) calendar days of the end of the subject calendar month. [...***...]. Each Party shall have the right to terminate this Agreement, upon written notice of no less than ten
(10) calendar days to the other Party, if [...***...]. 
 Upon approval and subsequent launch of the Product, Mylan
will deduct its Distribution and Storage Fee along with its royalty on a monthly basis and send the remaining [...***...] of Net Sales to Insys via a wire to an institution designated by Insys. At the end of each calendar quarter, the Parties
will determine if there were any rebates or returns that may need to be accounted for in the three (3) prior month’s Net Sales, and either Party will reconcile with a payment to the other Party within thirty (30) days of the
discovery. 
 7.6 Record Keeping. During the Term of this Agreement and for two (2) years thereafter, or for such
longer period as may be required by Law, Mylan shall prepare and retain accurate books and records as are needed to determine Net Sales and Net Profits. Such records shall be made available for reasonable review, audit and inspection upon reasonable
notice, upon Insys’ request for the purpose of verifying Mylan’s calculations, payments made and due, and the basis for such calculations or payments. Audits and inspections shall be conducted by an independent Third Party who agrees to be
bound by a reasonable confidentiality agreement. Insys’ right to review, audit and inspect Mylan’s books and records under this Section 7.6 shall be limited to one (1) inspection per calendar year. 

  
 ***Confidential
Treatment Requested    10 

 ARTICLE 8 – PRODUCT DISTRIBUTION 

8.1 Promotion of the Product. During the Term of this Agreement, Mylan shall use Commercially Reasonable Efforts to promote the
Product in the Territory in order to maximize economic benefit to both parties to the fullest extent possible; provided, however, that Mylan shall not be deemed to have failed to abide by or have failed to perform in accordance with the foregoing
standard if Mylan is prevented from performing or is hindered in its performance by any act or omission of Insys or by Force Majeure. 
 8.2 Joint Steering Committee. During the launch and throughout the Term of this Agreement, the Parties shall act jointly through a Joint Steering Committee (“JSC”) for certain matters
that require cooperation beyond normal business dealings. [...***...]. 
 8.3 Launch Decisions and Timing. The
decision when and whether to launch the Product in the Territory shall be made jointly by Insys and Mylan, acting through the JSC. In order for Mylan to be in a position to timely and effectively launch the Product, the Parties will cooperate in
good faith through the JSC to determine and prepare for the launch date, including communicating with one another on an ongoing basis any developments which may reasonably affect the timing of the Product launch. 

ARTICLE 9 – OWNERSHIP OF APPLICATIONS, INTELLECTUAL 
 PROPERTY AND LEGAL EXPENSES 
 9.1 Ownership of ANDAs. Insys shall
own and maintain at its own cost all ANDAs and associated regulatory filings made in the Territory for the Product, or for any alternate version of the Product that Insys may develop and have approved during the term hereof. 

9.2 Legal Expenses. If Mylan and Insys or either of them is sued for patent infringement in connection with the filing of an ANDA
for the Product in the Territory during the Term of this Agreement, then Insys shall have the right to control the defense of such litigation, to select and direct counsel, and to decide whether to settle or try any case. [...***...] discovery
requests and producing documents and things as may be necessary, and Insys bear the cost of such activities. 
 ARTICLE 10
INSURANCE AND INDEMNIFICATION 
 10.1 Product Liability Insurance. Each Party shall, during the Term of this
Agreement and for two (2) years after termination or expiration of this Agreement, obtain and maintain at its own cost and expense from a qualified captive insurance company (provided however that Mylan may satisfy all or part of its obligation
through its insurance carrier) product liability insurance providing protection against any and all claims, demands, and causes of action arising out of any defects, alleged or otherwise, of the Product or its use, design, labeling or manufacture,
or any material incorporated in the Product. [...***...]. Each Party agrees, upon request, to name the other Party as an additional insured on such policy and to furnish the other Party with a certificate of insurance evidencing such insurance
coverage (at the execution of this Agreement and at each subsequent renewal with [...***...] notice of cancellation or non-renewal), and the insured Party shall not at any time act pursuant to this Agreement unless such insurance is in effect.

  
 ***Confidential
Treatment Requested    11 

 10.2 Indemnity by Insys. Insys agrees to indemnify, defend and hold harmless Mylan
and its Affiliates and their respective directors, officers, employees, consultants, representatives and agents from and against any and all Losses relating to: (i) any material breach by Insys of its representations, covenants or warranties in
this Agreement; (ii) any negligence or willful misconduct of Insys or its Affiliates and their respective directors, officers, employees, consultants, representatives and agents, in the exercise of any of Insys’ rights or the performance
of any of Insys’ obligations under this Agreement; (iii) any failure to perform whatsoever regarding the manufacture or supply of the Product or any other obligations on the part of the Third Party Manufacturer; and (iv) all claims
made by a Third Party relating to patent infringement associated with Mylan’s sale of the Product in the Territory. 

10.3 Indemnity by Mylan. Mylan agrees to indemnify, defend and hold harmless Insys and its Affiliates and their respective
directors, officers, employees, consultants, representatives and agents from and against any and all Losses relating to (i) any material breach by Mylan of its representations, covenants or warranties in this Agreement, and (ii) any
negligence or willful misconduct of Mylan or its Affiliates and their respective directors, officers, employees, consultants, representatives and agents, in the exercise of any of Mylan’s rights or the performance of any of Mylan’s
obligations under this Agreement, and (iii) Mylan’s commercialization of the Product in violation of this Agreement. 

10.4 Procedure. A Party seeking indemnification under this Agreement (“Indemnified Party”) shall promptly notify, in
writing, the other Party (“Indemnifying Party”) of the assertion of any claim or discovery of any fact upon which the Indemnified Party intends to base a claim for indemnification. An Indemnified Party’s failure to so notify the
Indemnifying Party shall not, however, relieve such Indemnifying Party from any liability under this Agreement to the Indemnified Party with respect to such claim except to the extent that such Indemnifying Party is actually denied, during the
period of delay in notice, the opportunity to remedy or otherwise mitigate the event or activity(ies) giving rise to the claim for indemnification and thereby suffers or otherwise incurs additional Losses as a result of such failure. The
Indemnifying Party, while reserving the right to contest its obligations to indemnify, shall be responsible for the defense of any claim, demand, lawsuit or other proceeding in connection with which the Indemnified Party claims indemnification. The
Indemnified Party shall have the right at its own expense to participate jointly with the Indemnifying Party in the defense of any such claim, demand, lawsuit or other proceeding, but with respect to any issue involved in such claim, demand, lawsuit
or other proceeding with respect to which the Indemnifying Party has acknowledged its obligation to indemnify the Indemnified Party, the Indemnifying Party shall have the right to select counsel, settle, try or otherwise dispose of or handle such
claim, demand, lawsuit or other proceeding on such terms as the Indemnifying Party shall deem appropriate, subject to any reasonable objection of the Indemnified Party. An Indemnifying Party’s right to control, select counsel for, settle,
defend, try or otherwise dispose of or handle a claim, demand, lawsuit or other proceeding, does not give the Indemnifying Party the right: (i) to admit wrongdoing of any kind by or on behalf of the Indemnified Party; (ii) to falsely
disparage the reputation of the Indemnified Party; (iii) to cause the Indemnified Party to be debarred; or (iv) to agree by or on behalf of the Indemnified Party to the imposition upon it of any monetary or other liability or obligation
which cannot and/or will not be fully assumed and performed by the Indemnifying Party. 
 10.5 The Parties’
indemnification obligations under this Agreement shall survive termination or expiration of this Agreement for the period of the statute of limitations, as 

  
 12 

 
determined by a court of competent jurisdiction, applicable to each claim, demand, lawsuit or other proceeding giving rise to any Loss. 

ARTICLE 11 REPRESENTATIONS AND WARRANTIES 
 11.1 Mylan warrants and represents the following: 
 11.1.1 Mylan is
a corporation duly organized, validly existing and in good standing under the laws of the State of West Virginia, U.S.A. 

11.1.2 Mylan has all requisite power and authority to enter into this Agreement and has the requisite skill, knowledge, staffing,
financial resources and ability to carry out its obligations hereunder. The person signing this Agreement has the necessary corporate authority to legally bind Mylan to the terms set forth herein. 

11.1.3 Mylan’s execution of this Agreement and performance of the terms set forth herein will not cause Mylan to be in
conflict with or constitute a breach of any agreement or understanding with any Third Party. 
 11.1.4 To Mylan’s
knowledge and belief, there are no suits, actions, claims, proceedings, or investigations pending or threatened by or before any court, by any governmental agency or any person or entity relating to the matters set forth herein. 

11.1.5 Mylan’s execution of this Agreement and performance hereunder do not and will not be in material conflict with any
law, ordinance, statute or regulation. 
 11.1.6 Mylan is not debarred and Mylan has not and will not knowingly use in
any capacity the services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992. 
 11.1.7 Mylan has and will maintain throughout the Term of this Agreement all permits, licenses, registrations and other forms of governmental authorization and approval as required by applicable
laws in order for Mylan to execute and deliver this Agreement and to perform its obligations hereunder in accordance with all laws that are applicable to Mylan. 
 11.1.8 If at any time any of these representations and warranties is no longer accurate, Mylan shall immediately notify Insys of such fact. 

11.2 Insys warrants and represents the following: 
 11.2.1 Insys is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. 

11.2.2 Insys has all requisite power and authority to enter into this Agreement and has the requisite skill, knowledge, staffing,
financial resources, facilities and ability to carry out its obligations hereunder. The person signing this Agreement has the necessary corporate authority to legally bind Insys to the terms set forth herein. 

  
 13 

 11.2.3 Insys’ execution of this Agreement and performance of the terms set forth
herein will not cause Insys to be in conflict with or constitute a breach of any agreement or understanding with any Third Party. 
 11.2.4 To Insys’ knowledge and belief, there are no suits, actions, claims, proceedings, or investigations pending or threatened by or before any court, by any governmental agency or any
person or entity relating to the matters set forth herein. 
 11.2.5 Insys’ execution of this Agreement and
performance hereunder do not and will not be in material conflict with any law, ordinance, statute or regulation. 
 11.2.6
Insys is not debarred and Insys has not and will not knowingly use in any capacity the services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992. 

11.2.7 Insys has and will maintain throughout the Term of this Agreement all permits, licenses, registrations and other forms of
governmental authorization and approval as required by applicable laws in order for Insys to execute and deliver this Agreement and to perform its obligations hereunder in accordance with all laws that are applicable to Insys. 

11.2.8 That the Product does not violate or infringe the intellectual property rights of any Third Party. 

11.2.9 Insys’s third party manufacturer’s facility and all Product supplied hereunder shall comply with all Applicable
Laws and the Technical Agreement and meet all Specifications, and Insys shall perform and document all manufacturing and supply activities contemplated herein in compliance with all Applicable Laws. Without limiting the foregoing, at the time
of delivery to Mylan, none of the Product shall be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act, or equivalent regulations promulgated by the applicable Regulatory Authority in the Territory, as amended and in
effect at the time of shipment. 
 11.2.10 All Product(s) supplied by Insys under this Agreement shall least
eighty five (85%) percent shelf life remaining at the time of delivery of such Product(s) to Mylan or its designee. 

11.2.11 Title to all Product(s) provided to Mylan under this Agreement shall pass as provided in this Agreement, free and clear of
any security interest, lien, or other encumbrance. 
 11.2.12 The manufacture and supply of Product(s) hereunder shall
not infringe or misappropriate any intellectual property right of any third party. 
 ARTICLE 12 TERM AND TERMINATION

 12.1 Term. The Term of this Agreement shall commence on the Effective Date and shall continue until the
[...***...] of the first commercial sale of the Product in the Territory by Mylan, unless earlier terminated in accordance with the provisions of this Agreement. This Agreement shall automatically be extended for an additional
[...***...] following the [...***...] 

  
 ***Confidential
Treatment Requested    14 

 
of the first commercial sale of the Product in the Territory, unless either Party gives written notice to the other of its intention not to extend the Term of this Agreement at least one hundred
and eighty (180) calendar days prior to the end of the initial [...***...]. 
 12.2 Termination. 

12.2.1 This Agreement may be terminated by mutual written agreement of the Parties or by either Party upon forty-five
(45) calendar days’ prior written notice to the other Party if such other Party breaches any material provision or warranty of this Agreement and fails to cure that breach within such forty-five (45) calendar day period; provided,
however, that if the breaching Party is diligently pursuing a cure in good faith, the cure period shall be extended for such reasonable time as may be necessary to enable the breaching Party to complete such cure. In the event that a cure period
relevant to a breach by Insys is extended beyond the forty-five (45) calendar day period as set forth in the previous sentence, then Mylan shall have the right to use alternative site(s) for the manufacture of the Product subject to the
provisions of Section 4.4 of this Agreement. Upon the cure of the breach by Insys, Insys shall resume manufacturing subject to the mutual agreement of the Parties, which shall not be unreasonably withheld. Any notice of material breach under
this Section shall specify the default complained of, setting forth the underlying reasons for its belief a default has occurred and the remedy sought. The Party allegedly in default may cure the asserted breach or pursue the dispute resolution and
arbitration process specified in Section 12.8 within the notice period. If arbitration is demanded the Agreement shall continue in full force and effect as if the alleged breach had not occurred, pending the outcome of such arbitration.

 12.2.2 Either Party may terminate this Agreement on immediate notice if at any time the other Party:
(a) voluntarily files in any court pursuant to any statute of any governmental authority a petition in bankruptcy or insolvency or for the appointment of a receiver or trustee of such Party or of its assets; (b) shall be served with an
involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) calendar days after the filing thereof; (c) shall be a Party to any dissolution or liquidation; or
(d) makes a general assignment for the benefit of creditors. 
 12.2.3 Insys may terminate this agreement if Mylan
fails to launch the Product one hundred and twenty (120) calendar days after the Product is approved by the FDA, provided Insys has made the Product available for launch to Mylan. 

12.2.4 Mylan may terminate this Agreement immediately upon notice, in the event of a negative outcome of a quality audit under
Section 2.1 of this Agreement. 
 12.2.5 Termination of this Agreement for any reason shall be without prejudice to:
(a) Insys’ right to receive all payments due from Mylan, if any, as of the effective date of such termination; (b) Mylan’s right to receive all payments due from Insys, if any, as of the effective date of such termination;
(c) Mylan’s right to sell such Product remaining in its inventory, and at Mylan’s option, Mylan may elect to take delivery of and sell Product covered by any purchase order issued by Mylan prior to the effective date of termination;
and (d) any other legal, equitable, or administrative remedies as to which either Party is or may become entitled. Also Mylan shall be entitled to fulfill all existing contracts and all existing purchase

  
 ***Confidential
Treatment Requested    15 

 
orders after any termination whatsoever, and Insys shall supply the required Product therefore as provided for above in Section 4.3. 

ARTICLE 13 MISCELLANEOUS PROVISIONS 
 13.1 Governing Law. This Agreement shall by governed by the laws of the Commonwealth of Pennsylvania. 
 13.2 Confidentiality. The existence of this Agreement and its terms, and all communications between the Parties and their representatives relating to the subject matters of this Agreement shall be
considered Confidential Information under the existing Confidentiality Agreement between Mylan (or its Affiliate) and Insys, and shall not be disclosed by either Party except as authorized by the Confidentiality Agreement or required by law. All
confidential communications between the Parties pertaining to legal matters shall be conducted subject to a Common Interest Privilege Agreement between the Parties. 
 13.3 Licenses and Permits. Each Party shall, at its sole cost and expense, maintain in full force and effect all necessary licenses, permits, and other authorizations required by law in order to
carry out its duties and obligations hereunder. 
 13.4 Independent Contractors. This Agreement shall not constitute or
give rise to any employer-employee, agency, partnership, or joint venture relationship among or between the Parties, and each Party’s performance hereunder is that of a separate, independent entity in pursuit of a common purpose. 

13.5 No Modification. None of the terms of this Agreement shall be amended or modified except in writing signed by both Parties.

 13.6 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of Mylan and Insys and
their successors and assigns of all or substantially all of either Party’s business or assets. Any change of control of either Party shall not affect either Party’s rights or obligations under this Agreement. Except for an assignment to an
Affiliate of a Party, neither Party shall assign or transfer any of its rights or obligations under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld. Each Party shall be entitled to
assign all or any of its rights or obligations under this Agreement to an Affiliate or to a successor entity by way of merger or acquisition of substantially all of the assets of the assigning Party; provided the Affiliate or other successor entity
expressly assumes those rights, duties and obligations under this Agreement and the Agreement itself, and the Affiliate or other successor is a financially capable business entity. The assigning Party shall provide the other Party written notice of
any such assignment pursuant to this Section as soon as practicable thereafter. Any assignment or transfer in contravention of this Agreement shall be null and void. 
 13.7 Entire Agreement. This Agreement constitutes the entire agreement between the Parties respecting the subject matter hereof and supersedes all previous term sheets, correspondence and any and
all other writings and understandings. 

  
 16 

 13.8 Dispute Resolution / Arbitration. All disputes between the Parties relating to
or arising out of this Agreement, including but not limited to disputes, claims, defenses involving or requiring the interpretation, validity, enforceability, alleged breach or performance of this Agreement, shall be subject to the following dispute
resolution procedure. 
 [...***...]. 
 If the Parties cannot resolve their dispute through non-binding mediation, then the matter shall be finally settled under the auspices of and in accordance with the then-current Commercial Rules of the
American Arbitration Association. The arbitration proceedings shall be conducted at a location, date and time determined by the arbitrator(s). In the event of a conflict between the procedures set forth herein and the Commercial Rules, the
procedures set forth in this Section shall take precedence. 
 If monetary claims asserted in the arbitration are less than
$100,000, the dispute shall be heard and decided by a single arbitrator, but if any monetary claim is in excess of $100,000, the dispute shall be heard and decided by a panel of three arbitrators. If a three-person panel of arbitrators is employed,
then all decisions by the panel shall be by a majority of the arbitrators. 
 The arbitrator(s) shall allow the parties to
obtain discovery as may reasonably be requested by a Party, including use of interrogatories, depositions, and inspections of things or land. 
 The arbitration shall be conducted over the course of consecutive business days and weeks. The hearing shall be recorded stenographically and a transcript prepared if requested by either Party. The
expense of such hearing shall be borne equally by the Parties. Not less than ten (10) calendar days prior to the hearing, the Parties shall submit briefs to the arbitrator(s) setting for each Party’s contentions concerning the facts and
the law. Within thirty (30) calendar days following the close of the hearing, the Parties shall submit post-hearing briefs to the arbitrator(s). Within thirty (30) calendar days after the timely submission of post-hearing briefs, the
arbitrator(s) shall enter a written award concisely setting forth the grounds for the decision. 
 The arbitrator(s) shall
decide the dispute by applying the law selected by the Parties in this Agreement. 
 The decision of the arbitrator(s) shall be
final and binding and any award rendered thereon may be entered in any court having jurisdiction. 
 Nothing in this Section
restricts either Party’s freedom to seek urgent relief to preserve a legal right or remedy, or to protect a proprietary or trade secret right, or to otherwise seek emergency legal or equitable remedies necessary to preserve or restore the
status quo ante pending the outcome of arbitration. 
 13.9 Limitation of Liability. With the exception of matters
of confidentiality or indemnification, in no event shall either Party or their respective Affiliates be liable to the other Party or its Affiliates for special, punitive, indirect, incidental, exemplary or consequential loss or damage, or for lost
profits, based on a contract, tort, or any other legal theory, arising out of any breach of this Agreement or otherwise relating to the subject matter of this Agreement, except as may be specifically and expressly stated in this Agreement.

  
 ***Confidential
Treatment Requested    17 

 13.10 Severability. To the extent any provision or Term of this Agreement is or
becomes unenforceable or invalid by operation of Law, such unenforceability or invalidity shall not affect the remaining provisions of this Agreement. The Parties agree to renegotiate in good faith a substitute provision that to the extent possible
accomplishes the original business purpose of the provision held to be unenforceable or invalid. 
 13.11 Construction.
The language in all parts of this Agreement shall be construed, in all cases, according to its plain meaning. The Parties acknowledge that each Party and its legal counsel have reviewed this Agreement and that any rule of construction to the effect
that any ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation of this Agreement. The Article and section headings and captions are placed herein merely as a matter of convenience and shall not affect
the construction or interpretation of any of the provisions of this Agreement. 
 13.12 No Third Party Benefit. This
Agreement shall be binding upon and inure solely to the benefit of the Parties, their respective Affiliates, and their successors and permitted assigns, and nothing in this Agreement, express or implied, is intended to or shall confer upon any Third
Party any right, benefits or remedies of any nature whatsoever under or by reason of this Agreement. 
 13.13 Further
Acts. Each of the Parties shall do, execute and perform and shall procure to be done and perform all such further acts, deeds, documents and things as the other Party may reasonably require from time to time give full effect to the terms of this
Agreement. 
 13.14 Press Releases. All press releases and other public announcements relating to this Agreement or the
transactions contemplated hereby will be prepared and issued only with the prior mutual consent of Mylan and Insys, except that Mylan may disclose freely that Insys is the manufacturer of the Product, and the Parties may otherwise make such
disclosures as are required by Law. 
 13.15 Costs. Each Party will pay its own costs and expenses in connection with the
negotiation, preparation, execution and performance of this Agreement, except as otherwise provided herein. 
 13.16
Notices. Any notices given under this Agreement shall be in writing, sent by overnight delivery by a nationally recognized service (e.g. FedEx) and shall be deemed effective on the date of mailing. Unless otherwise changed by notice in writing,
notices may be served at the following addresses: 
  

			
	If to Mylan:	  	If to Insys:
		  	
	Mylan Pharmaceuticals Inc.	  	Insys Therapeutics, Inc.
	781 Chestnut Ridge Road	  	10220 South 51st Street, Suite 2
	Morgantown, WV 26505	  	Phoenix, AZ 85044
	United States of America	  	Attn: Mike Babich
	Attn: Lynn Cayton	  	President and CEO
	Exec. Director, Business Dev	  	

  

  
 18 

 With a copy to: 
 Mylan Inc. 
 1500 Corporate Drive 

Canonsburg, PA 15317 
 United States of America 
 Attn: Global General Counsel 

13.17 Counterparts. This Agreement may be executed in one or more counterparts, each of which is to be considered an original and
taken together as one and the same document. Faxed or electronic images of signatures shall be effective as an original. 

13.18 Survival. Any provision of this Agreement, which by its nature must survive termination or expiration in order to achieve
the fundamental purposes of this Agreement, shall survive any termination or expiration of this Agreement. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 

  
 19 

 EXECUTED AND AGREED ON THE EFFECTIVE DATE FIRST SET FORTH ABOVE: 

 

									
	INSYS THERAPEUTICS, INC.	 		 	MYLAN PHARMACEUTICALS INC.
					
	By:	 	/s/ Michael Babich	 		 	By:	 	/s/ Anthony Mauro

									
					
	Printed Name:	 	Michael Babich	 		 	Printed Name:	 	Anthony Mauro

									
					
	Title:	 	Chief Executive Officer	 		 	Title:	 	President MPI

  
 20 

 SCHEDULE A 
 PRODUCT 
 [...***...] 

  
 ***Confidential
Treatment Requested    21 

 SCHEDULE B 

PHARMACOVIGILANCE RESPONSIBILITIES 
 [...***...] 

  
 ***Confidential
Treatment Requested    22 

 Routing Guide 
 & 
 Delivery Instructions 

November 5, 2010 

  
 23 

 [...***...] 

  
 ***Confidential
Treatment Requested    24Manufacturing Agreement

 Exhibit 10.14 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

MANUFACTURING AGREEMENT 
 DPT LAKEWOOD, LLC 
 AND 

INSYS THERAPEUTICS 
 Table of Contents 
  

							
	 I - DEFINITIONS
	  	 	4	  
			
	 1.1
	  	 ACT
	  	 	4	  
	 1.2
	  	 FDA
	  	 	4	  
	 1.3
	  	FORECASTED NEEDS	  	 	4	  
	 1.4
	  	LABEL, LABELED, OR LABELING	  	 	5	  
	 1.5
	  	MANUFACTURING FEE	  	 	5	  
	 1.6
	  	 LAUNCH YEAR
	  	 	5	  
	 1.7
	  	MATERIALS FEE	  	 	5	  
	 1.9
	  	 PACKAGING
	  	 	6	  
	 1.10
	  	 PRODUCT(S)
	  	 	6	  
	 1.11
	  	 SPECIFICATIONS
	  	 	6	  
		
	 II - PRODUCT MANUFACTURE AND SUPPLY
	  	 	6	  
			
	 2.1
	  	 MANUFACTURE AND PURCHASE
	  	 	6	  
	 2.2
	  	 SUPPLY OF MATERIALS
	  	 	7	  
	 (a)
	  	 Materials Supplied by COMPANY
	  	 	7	  
	 (b)
	  	 Materials Supplied by DPT
	  	 	8	  
	 (c)
	  	 Packaging and Labeling
	  	 	8	  
	 2.3
	  	 MATERIALS TESTING
	  	 	8	  
	 2.4
	  	 MATERIAL SAFETY DATA SHEETS
	  	 	9	  
	 2.5
	  	 COMMENCEMENT OF MANUFACTURING FOR NEW
PRODUCTS
	  	 	9	  
	 2.6
	  	 PURCHASE ORDERS
	  	 	9	  
	 (a)
	  	 Purchase of Products
	  	 	9	  
	 (b)
	  	 Forecasted Needs
	  	 	9	  
	 (c)
	  	 Time of Issuance
	  	 	10	  
	 (d)
	  	 Contents of Purchase Orders
	  	 	10	  
	 2.7
	  	 REJECTED PRODUCTS
	  	 	11	  
	 (a)
	  	 Rejection of Product by COMPANY
	  	 	11	  
	 (b)
	  	 Replacement of Rejected Product
	  	 	11	  
	 (c)
	  	 Responsibility for Costs
	  	 	11	  
	 (d)
	  	 Resolution of Conflict
	  	 	12	  
	 2.8
	  	 PRODUCT PRICE
	  	 	13	  
	 (a)
	  	 Manufacturing Fees
	  	 	13	  
	 (b)
	  	 Materials Fees
	  	 	13	  
	 2.9
	  	PAYMENT	  	 	14	  
	 2.10
	  	 LATE PAYMENT
	  	 	14	  
	 2.11
	  	 DISPOSAL COSTS
	  	 	15	  

							
	 III - SHIPMENT AND RISK OF LOSS
	  	 	15	  
			
	 3.1
	  	 SHIPMENT
	  	 	15	  
	 3.2
	  	 DELIVERY TERMS
	  	 	15	  
	 3.3
	  	 CLAIMS
	  	 	15	  
		
	 IV - TERM AND TERMINATION
	  	 	16	  
			
	 4.1
	  	 TERM
	  	 	16	  
	 4.2
	  	 TERMINATION
	  	 	16	  
	 4.3
	  	 PAYMENT ON TERMINATION
	  	 	16	  
	 4.4
	  	 SURVIVAL
	  	 	16	  
		
	 V - CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE
	  	 	17	  
			
	 5.1
	  	 CERTIFICATES OF ANALYSIS
	  	 	17	  
	 5.2
	  	 STABILITY TESTING
	  	 	17	  
	 5.3
	  	 VALIDATION WORK OR ADDITIONAL
TESTING
	  	 	17	  
	 5.4
	  	 FDA INSPECTION
	  	 	17	  
	 5.5
	  	 REGULATORY FILINGS
	  	 	18	  
		
	 VI - WARRANTIES
	  	 	18	  
			
	 6.1
	  	 CONFORMITY WITH SPECIFICATIONS
	  	 	18	  
	 6.2
	  	 COMPLIANCE WITH THE ACT
	  	 	18	  
	 6.3
	  	 CONFORMITY WITH FDA REGULATIONS AND
CGMP’S
	  	 	18	  
	 6.4
	  	 COMPLIANCE OF PACKAGING AND LABELING
WITH LAWS AND REGULATIONS
	  	 	18	  
	 6.5
	  	 ACCESS TO DPT’S FACILITIES
	  	 	19	  
	 6.6
	  	 DISCLAIMER
	  	 	19	  
		
	 VII - FORCE MAJEURE
	  	 	19	  
		
	 VIII - CHANGES TO PROCESS OR PRODUCT
	  	 	20	  
			
	 8.1
	  	 CHANGES BY COMPANY
	  	 	20	  
	 8.2
	  	 CHANGES BY DPT
	  	 	20	  
	 8.3
	  	 CHANGES BY REGULATORY AUTHORITIES
	  	 	20	  
	 8.4
	  	 OBSOLETE INVENTORY
	  	 	21	  
		
	 IX - CONFIDENTIAL INFORMATION
	  	 	21	  
			
	 9.1
	  	 CONFIDENTIAL INFORMATION
	  	 	21	  
	 (a)
	  	 Obligations of Confidentiality
	  	 	21	  
	 (b)
	  	 Exceptions
	  	 	22	  
	 (c)
	  	 DPT Business Model
	  	 	22	  
	 9.2
	  	 TRADEMARKS AND TRADE NAMES
	  	 	22	  
	 9.3
	  	 INVENTIONS AND PATENTS
	  	 	23	  
	 SECTION 8 REGARDING COLLABORATIVE EFFORTS OF THE
RESEARCH AND DEVELOPMENT SERVICES AGREEMENT BETWEEN DPT AND COMPANY DATED APRIL 17, 2009, IS
HEREBY INCORPORATED IN ITS ENTIRETY BY ITS REFERENCE AND SHALL REMAIN
IN EFFECT FOR THE TERM OF THIS AGREEMENT
	  	 	23	  
		
	 X - RESEARCH & DEVELOPMENT SERVICES
	  	 	23	  
			
	 10.1
	  	 R&D SERVICES
	  	 	23	  
	 (a)
	  	 Research Products
	  	 	23	  
	 (b)
	  	 Project Protocol
	  	 	23	  
	 (c)
	  	 Costs
	  	 	24	  
	 (d)
	  	 Obsolete Inventory
	  	 	24	  
		
	 XI - INDEMNIFICATION
	  	 	25	  
			
	 11.1
	  	 INDEMNIFICATION BY DPT
	  	 	25	  
	 11.3
	  	 INDEMNIFICATION BY COMPANY
	  	 	25	  
	 11.6
	  	 PATENT AND OTHER INTELLECTUAL PROPERTY
RIGHTS
	  	 	26	  

  
 2 

							
	 (a)
	  	 Warranty by COMPANY
	  	 	26	  
	 (b)
	  	 Warranty by DPT
	  	 	26	  
	 11.7
	  	 CONDITIONS OF INDEMNIFICATION
	  	 	27	  
		
	 XII - GENERAL PROVISIONS
	  	 	27	  
			
	 12.1
	  	 NOTICES
	  	 	27	  
	 12.2
	  	 ENTIRE AGREEMENT; AMENDMENT
	  	 	27	  
	 12.3
	  	 WAIVER
	  	 	28	  
	 12.4
	  	OBLIGATIONS TO THIRD PARTIES	  	 	28	  
	 12.5
	  	 ASSIGNMENT
	  	 	28	  
	 12.6
	  	 GOVERNING LAW AND ARBITRATION
	  	 	28	  
	 (a)
	  	 Governing Law
	  	 	28	  
	 (b)
	  	 Arbitration
	  	 	28	  
	 (c)
	  	 Mediation
	  	 	30	  
	 (d)
	  	 Costs
	  	 	32	  
	 12.7
	  	 SEVERABILITY
	  	 	32	  
	 12.8
	  	 HEADINGS, INTERPRETATION
	  	 	32	  
	 12.9
	  	 COUNTERPARTS
	  	 	32	  
	 12.10
	  	INDEPENDENT CONTRACTOR	  	 	32	  

  
 3 

 This Manufacturing Agreement (the “Agreement”) is made as of
this 24th day of May, 2011 (the “Effective
Date”) by and between Insys Therapeutics, a corporation organized under the laws of the State of Delaware with its principal place of business at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (hereinafter referred to as “COMPANY”) and DPT Lakewood, LLC, a
corporation organized under the laws of the State of Delaware with a place of business at 1200 Paco Way, Lakewood, New Jersey, 08701, including its affiliate DPT Laboratories, Ltd. (hereinafter collectively referred to as “DPT”).

 WITNESSETH: 
 WHEREAS, COMPANY is engaged in the distribution and sale of certain pharmaceutical and/or cosmetic products; and 
 WHEREAS, DPT owns and has a broad spectrum of technologies for the development, formulation, testing, control, manufacture, filling and distribution of pharmaceutical, over-the-counter and cosmetic
products; and 
 WHEREAS, COMPANY desires DPT to manufacture and sell the Products hereinafter defined to COMPANY, and
DPT desires to do so. 
 NOW, THEREFORE, in consideration of the mutual covenants hereinafter expressed, the parties
agree as follows: 
 I - DEFINITIONS 

 

	1.1	Act 

 “Act”
means the Federal Food, Drug and Cosmetic Act, as amended, and regulations promulgated thereunder. 
  

	1.2	FDA 

 “FDA”
means the United States Food and Drug Administration, or any successor entity thereto. 
  

	1.3	Forecasted Needs 

“Forecasted Needs” means COMPANY’s estimate of Products to be ordered from DPT for each of the eighteen (18) months
following the month in which such estimate is provided. 

  
 4 

	1.4	Label, Labeled, or Labeling 

 “Label”, “Labeled”, or “Labeling” means all labels and other written, printed, or graphic matter upon: (i) Product or any container or wrapper utilized with Product or
(ii) any written material accompanying Product. 
  

	1.5	Manufacturing Fee 

“Manufacturing Fee” means the fee paid by COMPANY to DPT for services required to manufacture and package Products. The
Manufacturing Fee is quoted in single final Product unit increments (i.e. by the bottle or tube). The Manufacturing Fee shall include services for incoming inspection and testing of materials, compounding of bulk, packaging Product, testing Product
for release, making Product ready for shipment, and minimum product documentation (one copy of Certificate of Analysis.) The Manufacturing Fee does not include, without limitation, any research & development support, package engineering
studies, validation support, FDA audit support, extensive reporting requirements, or additional laboratory testing performed by an outside testing laboratory or testing beyond that required in the Specifications. These services are in addition to
the Manufacturing Fee and shall be billed by the hour at DPT’s then-prevailing R&D hourly rate in accordance with Section XI contained herein. In addition, the Manufacturing Fee does not include warehousing or distribution of Product, any
materials costs or costs associated with establishing or manufacturing new materials such as art charges, die costs, plate costs, and packaging equipment change parts. 
  

	1.6	Launch Year 

 “Launch
Year” means a period of a variable number of months commencing on the first day of the month following the initial invoicing of Product which has been commercially manufactured by DPT in accordance with the terms and conditions of this
Agreement and ending on December 31 of the year of the initial invoicing. 
  

	1.7	Materials Fee 

“Materials Fee” is quoted in single final Product unit increments and is defined as DPT’s Standard Cost (“Standard
Cost” is the average actual cost to DPT of materials plus incoming freight, scrap/yield loss adjustments and any other recurring costs directly attributable to acquiring the material) [...***...] for administration and carrying costs.
Materials Fee does not include, without limitation, costs associated with establishing, testing or manufacturing components or new materials such as reference standards, reagents, art charges, die costs, mold or tooling costs, plate

  

							
		  	 	5	  	  	***Confidential Treatment Requested

 
costs, and packaging equipment change parts. These items will be invoiced to COMPANY at DPT’s cost on a net thirty (30) basis and COMPANY agrees to reimburse DPT for any such authorized
expenditures made on COMPANY’s behalf. 
  

	1.8	Material Safety Data Sheet 

“Material Safety Data Sheet” (“MSDS”) means written or printed material concerning a hazardous chemical which is
prepared in accordance with the regulations promulgated by the Occupational Safety & Health Administration, or any successor entity thereto. 
  

	1.9	Packaging 

“Packaging” means all primary containers, cartons, shipping cases, inserts or any other like material used in packaging, or
accompanying, Product. 
  

	1.10	Product(s) 

“Product(s)” means product(s) (as listed in Schedule A) manufactured, packaged, labeled and/or finished by DPT to meet the
Specifications (as hereinafter defined). 
  

	1.11	Specifications 

“Specifications” means the (i) raw material specifications (including chemical, micro, and packaging specifications);
(ii) sampling requirements (i.e., lab, chemical, and micro); (iii) compounding module, including compounding process and major equipment; (iv) intermediate specifications; (v) packaging module (including packaging procedures,
torque and fill weights); and (vi) finished Product specifications release criteria including DPT’s Acceptable Quality Limits (“AQL’s”). Specifications shall be established and/or amended from time to time upon the written
agreement of both DPT and COMPANY via a Change Control Request (“CCR”) in accordance with Section IX below. 
 II
- PRODUCT MANUFACTURE AND SUPPLY 
  

	2.1	Manufacture and Purchase 

Subject to the terms and conditions of this Agreement, DPT agrees that it will manufacture for and provide to COMPANY, and COMPANY agrees
that it will purchase from DPT, one hundred percent (100%) of the 

  
 6 

 
COMPANY’s requirements of the Products. COMPANY shall pay DPT for Products according to paragraph 2.8 below. DPT shall manufacture Products in accordance with the Specifications or pursuant
to exceptions approved by COMPANY, and in sufficient quantity to meet COMPANY’s Forecasted Needs for the length of this Agreement. 
  

	2.2	Supply of Materials 

  

	 	(a)	Materials Supplied by COMPANY 

 If COMPANY is to supply any material for manufacture of Products as set forth under this Section, COMPANY shall notify DPT, in writing, specifying which materials it will supply. COMPANY shall provide DPT
with said materials at COMPANY’s expense along with Certificates of Analysis and MSDS sheets relating to same, at a minimum of thirty (30) days prior to DPT’s scheduled production of Product requiring said materials and in sufficient
amounts for DPT’s manufacture of Product but not to exceed quantities necessary to support four (4) months of the most recently supplied Forecasted Needs or the minimum order quantity whichever is greater. COMPANY supplied material in
excess of these amounts shall be either subject to storage fees or returned to COMPANY. All COMPANY supplied material shall be shipped to DPT freight prepaid. In the event COMPANY ships or causes to ship such material freight collect, DPT shall
invoice COMPANY for the cost of the freight plus a reasonable administrative fee which invoice shall be paid promptly upon receipt. DPT is hereby authorized by COMPANY to return any portion of COMPANY supplied material for which no future production
is planned. COMPANY shall be responsible for the quality of all COMPANY-supplied materials. COMPANY shall be responsible for the payment of all personal property and other taxes incident to the storage of COMPANY-owned material at DPT. For each lot
of materials supplied by COMPANY, DPT shall perform the quality control and inspection tests as agreed to in the Specifications unless COMPANY has made arrangements in writing for pre-approved material. DPT shall have the right to reject any
pre-approved material which does not meet the Specifications in accordance with paragraph 2.3 below. DPT warrants that it will maintain, for the benefit of COMPANY, complete and accurate records of the inventory of all such COMPANY-supplied
materials. If requested by COMPANY, DPT will provide to COMPANY a monthly report of ending monthly inventory balance of each COMPANY supplied/owned materials stored at DPT. This reporting will be supplied exclusively on DPT forms. 

  
 7 

	 	(b)	Materials Supplied by DPT 

 DPT shall be responsible for supply, at the expense of COMPANY of all other commodities necessary for the manufacture of Products. All DPT supplied materials will be billed to COMPANY on the respective
invoice for Product, into which the DPT supplied materials was converted, as part of the Materials Fee, and in addition to the Manufacturing Fee, all in accordance with the provisions of paragraph 2.8 below. 

 

	 	(c)	Packaging and Labeling 

 COMPANY shall provide DPT with Specifications (including art proofs) for Packaging and Labeling, and DPT shall purchase, at the expense of COMPANY, Packaging and Labeling in accordance with the
Specifications. 
  

	 	(d)	Additional Charges 

COMPANY shall be responsible for any additional charges (including, but not limited to, items such as brokerage fees, courier expenses,
duty fees payable, etc.) that are incurred in the procurement of any materials and/or Packaging and Labeling components as detailed in the immediately preceding sub-sections (a), (b) and (c); required for the manufacture of the Products,
irrespective of which party to the Agreement is responsible for supplying such items. 
  

	 	(e)	Safety Stock 

 At
least annually, and more frequently depending on business conditions, COMPANY shall determine and inform DPT of the level of safety stock inventory for API and Materials, by Product, that DPT shall hold in its warehouse. COMPANY shall pay for such
safety stock inventory for API and Materials and associated storage fee as agreed upon in writing between the parties. 
  

	2.3	Materials Testing 

  
 8 

 All materials and packaging supplies shall, when received by DPT, be submitted to analysis
and evaluation in accordance with DPT’s SOP’s to determine whether or not said materials meet the Specifications. The cost of all such analyses and evaluations shall be borne by DPT, except as otherwise provided in paragraph 2.2 of this
Agreement. DPT agrees to maintain and, if necessary, make available records of all such analyses and evaluations. 
  

	2.4	Material Safety Data Sheets 

 Prior to DPT’s receipt and testing, and as a condition precedent of any testing or formulation work by DPT pursuant to this Agreement, COMPANY shall provide MSDS sheets to DPT for finished products
and all components necessary for the manufacture of Products. Any components or Products requiring disposal shall be presumed hazardous unless otherwise provided in the MSDS information provided. 

 

	2.5	Commencement of Manufacturing for New Products 

 No later than four (4) months prior to the initial calendar year of a new Product added to this Agreement, COMPANY agrees to notify DPT of its delivery requirements, including firm orders for same,
for the four (4) months and shall provide its Forecasted Needs for the first calendar year in order to ensure timely delivery of Product for initial sale and marketing. 

 

	2.6	Purchase Orders 

  

	 	(a)	Purchase of Products 

 COMPANY agrees to purchase from DPT all Products manufactured for COMPANY by DPT in accordance with COMPANY’s purchase orders or Forecasted Needs to the extent such Products meet the Specifications
or exceptions approved by COMPANY. Products shall be ordered by COMPANY by the issuance of separate, pre-numbered purchase orders in increments of full batches and in minimum order quantities. 

 

	 	(b)	Forecasted Needs 

 COMPANY shall provide DPT with a written, non-binding eighteen (18) month projection with specific data as to its Forecasted Needs. Such Forecasted Needs shall be updated by COMPANY monthly on or
before the 10th day of each calendar month on a rolling
eighteen (18) month basis. It is understood and agreed that with respect to all Forecasted Needs issued to DPT by COMPANY 

  
 9 

 
pursuant to the terms hereof, the forecast for the first four (4) months thereof shall constitute a firm order for Products, regardless of receipt of COMPANY’s actual purchase order.
Thereafter, COMPANY shall provide DPT with a Purchase Order on or before the 10th day of each calendar month. DPT may produce Product up to thirty (30) days prior to the requested delivery date in order to accommodate fluctuations in production demands. The remaining fourteen
(14) months of the Forecasted Needs shall be utilized by DPT for purposes of material acquisition on behalf of COMPANY and DPT production planning. DPT shall attempt to minimize the material inventory purchased on behalf of COMPANY. Certain
materials, however, may have long lead times and/or require a minimum order quantity. Therefore, DPT may order the chemical and packaging components necessary to support up to six (6) months of COMPANY’s Forecasted Needs, or the applicable
minimum order quantity, whichever is greater. Should COMPANY subsequently reduce its Forecasted Needs, COMPANY will be financially responsible for any material purchased by DPT on COMPANY’s behalf. Any such material which is subsequently
rendered in excess of that required to support up to six (6) months of COMPANY’s Forecasted Needs may be subject to storage and inventory caring fees. DPT may require a deposit for such materials and such materials may also be subject to
storage and inventory carrying cost fees. 
  

	 	(c)	Time of Issuance 

COMPANY shall issue written purchase orders for Products to DPT at least one hundred twenty (120) days prior to the requested
delivery dates if the requirements are at or below one hundred twenty-five percent (125%) of the applicable Forecasted Needs, and at least one hundred fifty (150) days prior to the requested delivery dates if the requirements exceed the
Forecasted Needs by more than one hundred twenty-five percent (125%). 
  

	 	(d)	Contents of Purchase Orders 

 COMPANY’s purchase orders shall designate the desired quantities of Products, delivery dates and destinations. This Agreement allows for up to three (3) shipping destinations per batch of
Product. Additional destinations can be accommodated for a shipping preparation fee to be negotiated by DPT and COMPANY. 

  
 10 

	2.7	Rejected Products 

  

	 	(a)	Rejection of Product by COMPANY 

 COMPANY may reject any Product which fails to meet the Specifications, provided that such failure impairs the safety or efficacy of the Product (“Rejected Product”). COMPANY shall, within twenty
(20) days after its receipt of any shipment of Product and related Certificate of Analysis of Product batch (as described in paragraph 5.1 hereof), notify DPT in writing of any claim relating to rejected Product batch and, failing such
notification, shall be deemed to have accepted such Product batch. Such notice to DPT shall specify why the Product batch failed to perform to Specifications. COMPANY shall grant to DPT the right to inspect or test said Product batch. All Products
shall be submitted to inspection and evaluation in accordance with DPT’s SOP’s to determine whether or not said Products meet the Specifications. 
  

	 	(b)	Replacement of Rejected Product 

 As to any Rejected Product pursuant to paragraph 2.7(a) above (including phases of or complete batches of bulk product), DPT shall replace such Rejected Product (in an agreed upon batch order quantity,
but in no event less than full batch increments) promptly after all materials are available to DPT for the manufacture. If requested, DPT shall make arrangements with COMPANY for the return or disposal of Rejected Product. 

 

	 	(c)	Responsibility for Costs 

 For the initial three (3) commercial batches and all validation batches of a Product produced by DPT, or in the event a Rejected Product is due to COMPANY supplied information, formulations or
materials, COMPANY shall bear one hundred percent (100%) of all costs directly related to and invoiced for Rejected Product including cost of destruction of the Rejected Product, which shall be conducted by COMPANY in accordance with all
applicable laws and regulations. Upon the completion of all necessary validation batches and in the event a validated Product is rejected due to DPT’s failure to follow cGMP’s and/or comply with applicable written procedures and such
failure renders the Product unmarketable, DPT shall bear one hundred percent (100%) of the manufacturing fees, costs of all materials (except for the Aptar device) supplied by DPT and cost of destruction. [...***...]. In the event a
validated Product does not meet final Specifications and results in a Rejected Product, but such failure is not due to either COMPANY supplied information or DPT’s failure to follow written

  

							
		  	 	11	  	  	***Confidential Treatment Requested

 
procedures, the COMPANY shall bear all Materials Fees with DPT bearing all Manufacturing Fees related to Rejected Product, and with destruction to be paid by the COMPANY. Destruction of Rejected
Product shall be in accordance with all applicable laws and regulations and the party conducting the destruction shall indemnify the other party hereto for any liability, costs or expenses, including attorney’s fees and court costs, relating to
a failure to dispose of such Product in accordance with such laws and regulations. The party conducting the destruction shall also provide to the other party hereto all manifests and other applicable evidence of proper destruction as may be
requested by applicable law. 
  

	 	(d)	Resolution of Conflict 

 In the event of a conflict between the test results of DPT and the test results of COMPANY with respect to any shipment of Product batch, a sample of such Product batch shall be submitted by DPT to an
independent laboratory or recognized industry expert acceptable to both parties for testing against the Specifications utilizing the methods set out in the Specifications. The fees and expenses of such laboratory testing shall be borne entirely by
the party against whom such laboratory’s findings are made. If results from the independent laboratory are inconclusive, final resolution will be settled in accordance with paragraph 12.6 (b) below. 

 

	 	(e)	Recalled Product 

In the event (I) any government authority issues a request, directive or administrative order that Product be recalled, or
(ii) a court of competent jurisdiction orders a Product recall, or (iii) the COMPANY reasonably determines that the Product should be recalled, the parties shall take all appropriate corrective actions which are reasonable under the
circumstances. In the event that such recall results solely from the breach of DPT’s warranties under this Agreement, DPT shall be responsible for the administrative expenses of the recall in any case not to exceed [...***...] per recall
incident as well as for the cost of replacing the recalled Product. In the event the recall results from the breach of COMPANY’s warranties under this Agreement, COMPANY shall be responsible for all of the expenses of the recall. For the
purposes of this Agreement, administrative expenses of the recall shall be 

  

							
		  	 	12	  	  	***Confidential Treatment Requested

 
the expenses of notification, destruction or return of the recalled Product; including any reasonable out-of-pocket costs incurred by the parties in connection with any corrective action.

  

	2.8	Product Price 

  

	 	(a)	Manufacturing Fees 

The initial Manufacturing Fees to be paid by COMPANY to DPT are listed in Schedule A. The parties hereto agree that the Manufacturing Fees
set out in Schedule A shall be re negotiated, in good faith, at the beginning of each calendar year. If the parties are unable to agree on a re-negotiated price at least thirty (30) days prior to the start of a new twelve (12) month
period, then this Agreement, effective the first day of January of the new twelve (12) month period, shall continue in force with prices being adjusted to reflect the change in the most recently published monthly “Producer Price Index for
Pharmaceutical Preparation Manufacturing”, issued by the Bureau of Labor Statistics, US Department of Labor (“PPI”), or comparable successor index, in July of the preceding year as compared to the same month of the year prior thereto
until such time as to when price negotiation can be completed. 
 In addition, Manufacturing Fees are based on annual volumes for
Products. DPT reserves the right to re-evaluate Manufacturing Fees at the beginning of the second calendar year (and each calendar year thereafter) in the event that actual volumes differ from those volumes listed in Schedule A. by more than ten
percent (10%). 
 Prices for new Products or new Product sizes, new batch sizes or product configuration changes not initially
included in Schedule A, shall be negotiated and DPT and COMPANY shall arrive at a mutual agreement with respect to prices at the time said new Products or new Product sizes are added to Schedule A. 

If a negotiated price cannot be agreed upon, final pricing for any of the above will be settled in accordance with paragraph 12.6
(b) below. 
  

	 	(b)	Materials Fees 

The Materials Fee to be paid by COMPANY to DPT shall be listed in Schedule A within one hundred twenty (120) days of commencement of
the initial commercial products of the applicable Product. The Materials Fee will be adjusted once annually at the 

  
 13 

 
beginning of each calendar year and Schedule A shall be amended accordingly based on changes in DPT’s standard costs for materials. In the event, however, the cost of a material increases
during any calendar year greater than ten percent (10%), DPT may promptly upon the effective date of such increase adjust its invoice price for said material to COMPANY to compensate for the increase. 

Material Fees for new Products or new Product sizes, new batch sizes or product configuration changes not initially included in Schedule
A, shall be established at the time of first production. 
  

	2.9	Payment 

 Payment for all
deliveries of Product and services shall be made in U.S. Dollars (USD), net thirty (30) days after the date of DPT’s invoice therefor. Invoices shall be generated upon shipment of Product from DPT. Total invoice price shall be equal to the
quantity of Product times the Total Price per unit effective on the date of Product release, as listed in Schedule A. Payments shall be made by certified check, via wire transfer or through other instrument accepted by DPT. Fund transfers by wire
should be made to the following: 
  

					
		  	Account name:	  	[...***...]
		  	Account number:	  	[...***...]
		  	Bank name:	  	Bank of America
		  	ABA routing number:	  	[...***...]
		  	SWIFT code (US$)	  	[...***...]
		  	Bank location: 	  	901 Main Street, 8th Floor
		  		  	Dallas, Texas 75202
		  	Contact:	  	[...***...]
		  		  	[...***...]

  

	2.10	Late Payment 

 A late fee
of one and one-half percent (1.5%) of total invoice can be added each month for late payments. DPT, at its sole discretion, has the right to discontinue COMPANY’s credit on future orders and to put a hold on any production or shipment of
Product if COMPANY’s account is not current. Such hold on production or shipment shall not constitute a breach of this Agreement by DPT. In the event credit is discontinued, a one hundred percent (100%) material deposit paid by COMPANY to
DPT will be required prior to DPT ordering materials. In addition, a fifty 

  

							
		  	 	14	  	  	***Confidential Treatment Requested

 
percent (50%) Manufacturing Fee deposit will be required prior to DPT manufacturing any Product and the balance of the invoice must be paid in full prior to shipment. 

 

	2.11	Disposal Costs 

 DPT
reserves the right to invoice COMPANY for all disposal costs, related to manufacture of the Products, unless the disposal relates to a Rejected Product causes by the failure of DPT to follow established written procedures. 

III - SHIPMENT AND RISK OF LOSS 
  

	3.1	Shipment 

 Shipment of
Product shall be in accordance with COMPANY instructions, provided that shipment is made in accordance with all relevant statutory requirements. Product will be shipped to COMPANY or its designee immediately upon release, freight collect. At
COMPANY’s request, DPT may hold Product in DPT’s warehouse for a storage fee. Product held at DPT will be subject to payment as if the product was shipped in accordance with paragraph 2.9 above. If COMPANY requests DPT to make any
miscellaneous small shipments of Product, material, or other items on COMPANY’s behalf, COMPANY agrees to reimburse DPT for any shipping charges incurred. 
  

	3.2	Delivery Terms 

 The
delivery terms of the Products detailed in Schedule A hereof shall be Ex Works (“EXW” Incoterms 2010) DPT’s plant of manufacture, freight collect. Title to, and risk of loss for, Product, shall transfer from DPT to COMPANY when DPT
makes the Product available to COMPANY at its plant of manufacture. COMPANY shall bear all risk of loss, delay, or damage in transit, as well as cost of freight and insurance. 

 

	3.3	Claims 

 The weights,
tares and tests affixed by DPT’s invoice shall govern unless established to be incorrect. Claims relating to quantity, weight and loss or damage to any Product sold under this Agreement shall be waived by COMPANY unless made within thirty
(30) days of receipt of Product by COMPANY. 

  
 15 

 IV - TERM AND TERMINATION 

 

	4.1	Term 

The initial term of this Agreement shall commence on the Effective Date hereof and will continue until
December 31 of the fifth (5th) calendar year
following the Launch Year, unless sooner terminated pursuant to paragraph 4.2 below. This Agreement shall thereafter automatically renew for periods of twenty-four (24) months, unless any party shall give notice to the other to the contrary at
least twenty four (24) months prior to the expiration of the initial term or any renewal term of the Agreement. 
  

	4.2	Termination 

 This
Agreement may be terminated at any time upon the occurrence of either of the following events: 
  

	 	(a)	The failure of either party to comply with its obligations herein, which failure is not remedied within sixty (60) days after written notice thereof.

  

	 	(b)	Notice by either party to the other upon the insolvency or bankruptcy of the other party. 

 

	4.3	Payment on Termination 

In the event of the termination or cancellation of this Agreement for any reason besides DPT termination, and without prejudice to any
other rights and remedies available to DPT hereunder, COMPANY agrees to reimburse DPT the Materials Fee directly ordered for the manufacture of Products based on COMPANY’s Forecasted Needs as well as for work-in-process and finished Products.

  

	4.4	Survival 

 Termination of
this Agreement under paragraph 4.2 or due to expiration or cancellation shall not relieve either party of obligations or liability for breaches of this Agreement incurred prior to or in connection with termination, expiration or cancellation.
Sections VI, VII, IX, X, XI and XII hereof shall survive the termination or cancellation of this Agreement for any reason. 

  
 16 

 V - CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE 

 

	5.1	Certificates of Analysis 

DPT shall test each lot of Product purchased pursuant to this Agreement before delivery to COMPANY. Each Certificate of Analysis shall set
forth the items tested, specifications and test results for each lot delivered. DPT shall send one (1) Certificate of Analysis to COMPANY at the time of the release of Product. Extraordinary reporting or documentation, outside this Agreement,
may be subject to an additional charge by DPT. 
  

	5.2	Stability Testing 

 DPT
shall perform its standard stability test program as defined in DPT’s SOP’s or as separately agreed to in accordance with a CCR for each of the Products contained herein. COMPANY shall receive a copy of DPT’s Annual Product Review for
each Product as long as DPT is continuing to produce such Product for COMPANY and for as long as COMPANY’s account is current. If COMPANY elects to perform its own stability testing on Product, COMPANY agrees to provide DPT with a copy of the
results from such testing on an annual basis. 
  

	5.3	Validation Work or Additional Testing 

 It is understood by the parties hereto that the responsibility for any validation work shall be the sole responsibility of COMPANY. The parties agree that for any validation work or additional testing in
connection with the Product, DPT and COMPANY shall enter into a specific written Project Protocol establishing methodology and pricing for such services. It is understood between the parties hereto that if DPT is required by regulatory authority to
perform validation studies or additional testing in order to legitimately continue to engage in the manufacture of the Product for COMPANY and DPT and COMPANY cannot reach an agreement on a written Project Protocol, then DPT shall be under no
obligation to continue the manufacture of the Product affected by said regulation. 
  

	5.4	FDA Inspection 

 DPT shall
advise COMPANY if an authorized agent of the FDA or other governmental agency visits DPT’s manufacturing facility and requests or requires information or changes which specifically pertain to the Products. FDA audit time specific to Products
will be billed to COMPANY from DPT at the then-prevailing QA hourly rate. 

  
 17 

	5.5	Regulatory Filings 

COMPANY agrees to provide DPT with copies of any sections of NDA’s, ANDA’s, 510(k)’s or other regulatory filings applicable
to the Products manufactured and/or tested by DPT, and copies of any changes in or updates of same as they, from time to time, hereafter occur. 
 VI - WARRANTIES 
  

	6.1	Conformity with Specifications 

 DPT warrants that all Products sold pursuant to this Agreement will have been manufactured in accordance with the Specifications for the release of the Product or pursuant to exceptions approved by
COMPANY at the time of manufacture. 
  

	6.2	Compliance with the Act 

COMPANY shall bear sole responsibility for the validity of all test methods and appropriateness of all Specifications. In addition,
COMPANY shall bear sole responsibility for all regulatory approvals, filings, and registrations and adequacy of all validation, stability, and preservative efficacy studies. COMPANY further warrants that it has obtained any and all necessary
approvals from all applicable regulatory agencies necessary to manufacture and distribute all Products under this Agreement. 
  

	6.3	Conformity with FDA regulations and cGMP’s 

 Subject to the provisions set forth in paragraph 6.2 and 6.4 hereof, DPT warrants that all Products shall have been manufactured by DPT in compliance with applicable FDA regulations and current Good
Manufacturing Practices as that term is defined under the Act. 
  

	6.4	Compliance of Packaging and Labeling with Laws and Regulations 

 COMPANY warrants that all Labeling copy and artwork approved, designated or supplied by COMPANY shall be in compliance with all applicable laws and governmental regulations. Compliance with all federal,
state, and local laws and regulations concerning Packaging and Labeling shall be the sole responsibility of COMPANY, provided that DPT purchases such Packaging and Labeling as provided in paragraph 2.2 (c) hereof. COMPANY hereby represents and
warrants to DPT that all COMPANY designated formulas, components and artwork related to the 

  
 18 

 
Product do not violate or infringe any patent, copyright or trademark laws, and agrees to indemnify DPT, its employees, officers, directors and representatives for any claim, loss or damage
including reasonable attorney’s fees paid or incurred by any of them in connection therewith. 
  

	6.5	Access to DPT’s Facilities 

 COMPANY shall have access to DPT’s facilities at a mutually agreeable time for the sole purpose of auditing DPT’s compliance with current Good Manufacturing Practices and the Act. Such access
shall in no way give COMPANY the right to any of DPT’s confidential or proprietary information. Further, such audits shall normally be limited to every eighteen (18) months and three (3) employees of COMPANY who are subject to the
same requirements of confidentiality as COMPANY. 
  

	6.6	Disclaimer 

 DPT AND
COMPANY MAKE NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCT, LABELING OR PACKAGING; EXCEPT AS DETAILED HEREIN. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED. IN NO EVENT WILL DPT BE LIABLE FOR ANY LOSS OF PROFITS, LOSS OF USE, BUSINESS INTERRUPTION, COST OF COVER, OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH OR
ARISING OUT OF THE PERFORMANCE OF THIS AGREEMENT, WHETHER ALLEGED AS A BREACH OF CONTRACT OR TORTIOUS CONDUCT, INCLUDING NEGLIGENCE, EVEN IF DPT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. DPT’S LIABILITY UNDER THIS AGREEMENT FOR FIRST
PARTY DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, RESTITUTION, WILL NOT EXCEED, THE AMOUNT OF MANUFACTURING FEES PAID BY COMPANY TO DPT UNDER THIS AGREEMENT UP TO A MAXIMUM AMOUNT OF [...***...]. 

VII - FORCE MAJEURE 
 Failure of either party to perform its obligations under this Agreement shall not subject such party to any liability to the other if such failure is caused

  

							
		  	 	19	  	  	***Confidential Treatment Requested

 
by acts such as, but not limited to, acts of God, acts of terrorism, fires, explosion, flood, drought, war, riot, sabotage, embargo, strikes, compliance with any court order or regulation of any
government entity acting with color of right or by any other cause beyond the reasonable control of the parties, whether or not foreseeable. 
 VIII - CHANGES TO PROCESS OR PRODUCT 
  

	8.1	Changes by COMPANY 

 If
COMPANY at any time requests a change to Product and DPT agrees such change is reasonable with regard to Product manufacture; (i) such change shall be incorporated within the Master Batch Record and/or Specifications via a written CCR reviewed
and agreed upon by both DPT and COMPANY; (ii) The parties shall adjust the price of Product, if necessary, and Schedule A shall be amended accordingly; and (iii) COMPANY shall pay DPT for the costs associated with such change including,
but not limited to, any additional development or validation work required, charged at DPT’s then-prevailing R&D rates in accordance with Section XI contained herein. 

 

	8.2	Changes by DPT 

 DPT
agrees that any changes developed by DPT, which may be incorporated into the Product shall require the written approval of COMPANY via a CCR prior to such incorporation. At the time of such incorporation, such changes shall become part of the
Specifications. It is also agreed that any regulatory filings incident to any such change shall be the sole responsibility of COMPANY. 
  

	8.3	Changes by Regulatory Authorities 

 The parties agree that any changes required by regulatory authority, shall be incorporated into the Product as evidenced by the written approval of COMPANY via a CCR prior to such incorporation. At the
time of such incorporation, such changes shall become part of the Specifications. If DPT is required by regulatory authority to perform validation studies for purposes of validating new manufacturing process or cleaning procedures or new material
and finished Product assay procedures with respect to Product in order to continue to engage in the manufacture of said Product for COMPANY, such studies shall be conducted in accordance with paragraph 5.3 herein. Any costs to DPT resulting from the
operation of this paragraph shall be reimbursed by COMPANY. 

  
 20 

	8.4	Obsolete Inventory 

 Any
COMPANY-specific inventory including, but not limited to, materials, work-in-process, and Products rendered obsolete as a result of formula, artwork or packaging changes requested by COMPANY or by changes required by regulatory authority shall be
reimbursed to DPT by COMPANY at DPT’s Materials Fee. At such time and unless otherwise instructed by COMPANY agreed by DPT, DPT will ship the obsolete inventory to COMPANY for destruction by COMPANY. COMPANY shall bear one hundred percent
(100%) of all shipping and destruction costs related to said obsolete inventory. The destruction shall be in accordance with all applicable laws and regulations and COMPANY shall indemnify DPT for any liability, costs or expenses, including
attorney’s fees and court costs, relating to COMPANY’s failure to dispose of such inventory in accordance with such laws and regulations. COMPANY shall also provide DPT with all manifests and other applicable evidence of proper destruction
as may be requested by DPT or required by applicable law. If DPT does not receive disposition instructions from COMPANY within ninety (90) days from date of obsolescence, obsolete inventory remaining at DPT’s facilities shall be subject to
a deposit covering the standard cost of the obsolete inventory and storage fees. 
 IX - CONFIDENTIAL INFORMATION

  

	9.1	Confidential Information 

  

	 	(a)	Obligations of Confidentiality 

 All confidential information furnished by COMPANY to DPT, or by DPT to COMPANY, during the term of this Agreement, relating to the subject matter hereof, shall be kept confidential by the party receiving
said confidential information, except for purposes authorized by this Agreement, and shall not be disclosed to any person or firm, unless previously authorized in writing to do so, for a period of not less than five (5) years following the date
of disclosure. The party receiving said confidential information may, however, disclose the same to its responsible officers and employees who require said information for the purposes contemplated by this Agreement, provided that said officers and
employees shall have assumed like obligations of confidentiality. It is understood that all confidential information provided by either party shall be identified or marked as such. Any oral communications which are to be considered confidential
shall be reduced to writing and identified as confidential within thirty (30) days after disclosure. 

  
 21 

	 	(b)	Exceptions 

 Any
other provisions hereof to the contrary notwithstanding, it is expressly understood and agreed by the parties hereto that the obligations of confidence and nonuse herein assumed shall not apply to any information which: 

 

	 	(1)	is at the time of disclosure or thereafter so becomes a part of the public domain; or 

 

	 	(2)	was otherwise in the receiving party’s lawful possession prior to disclosure as shown by its written record; or 

 

	 	(3)	is hereafter disclosed to the receiving party by a third party purporting not to be in violation of an obligation of confidentiality to the disclosing party relative to
said information; or 

  

	 	(4)	is by mutual agreement of the parties hereto released from a confidential status; or 

 

	 	(5)	is required to be disclosed pursuant to regulatory or legal requirements. 

  

	 	(c)	DPT Business Model 

COMPANY acknowledges that as a contract manufacturing organization, DPT’s business involves the application of its expertise,
technology and know-how to numerous pharmaceutical and other products and that DPT retains the right (subject to its obligations under the applicable confidentiality provision or agreement) to apply such expertise, technology and know-how to a
variety of products or services. 
  

	9.2	Trademarks and Trade Names 

  

	 	(a)	Each party hereby acknowledges that it does not have, and shall not acquire any interest in any of the other party’s trademarks or trade names unless otherwise
expressly agreed. 

  

	 	(b)	Each party agrees not to use any trade names or trademarks of the other party, except as specifically authorized by the other party in writing both as to the names or
marks which may be used and as to the manner and prominence of use. 

  
 22 

	9.3	Inventions and Patents 

Section 8 regarding Collaborative Efforts of the Research and Development Services Agreement between DPT and COMPANY dated
April 17, 2009, is hereby incorporated in its entirety by its reference and shall remain in effect for the term of this Agreement. 
 X - RESEARCH & DEVELOPMENT SERVICES 
  

	10.1	R&D Services 

  

	 	(a)	Research Products 

From time to time, COMPANY may request, in writing, that DPT evaluate, develop, manufacture, test and/or provide price quotations for
certain new items which may become Products (hereinafter referred to as “Research Products”) on behalf of COMPANY. If DPT agrees to perform such services, DPT shall so notify COMPANY within sixty (60) days of its receipt of
COMPANY’s request. To the extent that DPT agrees to perform any services hereunder for COMPANY, DPT shall only be obligated to act in good faith and to use reasonable efforts to accomplish the desired results as outlined in a mutually agreed
upon Project Protocol. Nothing herein shall obligate DPT to achieve any specific results and DPT makes no warranties or representations that it will be able to achieve the desired results. 

 

	 	(b)	Project Protocol 

Should DPT agree to perform any services hereunder, DPT shall submit a written development proposal in the form of a Project Protocol to
COMPANY identifying DPT’s best estimate of the development costs. This estimate shall include, but not be limited to, labor hours for development, testing, scale up, stability, report writing, etc., as well as all reasonably foreseeable
associated tasks and expenses. If this estimate is acceptable to COMPANY and COMPANY so notifies DPT by approving the Project Protocol in writing, DPT shall begin work as outlined in the Protocol. It is understood between both parties that during
any development project unforeseen circumstances may evolve, including, but not limited to, termination of any further activity due to unacceptable results, significant reevaluation due to marginal results, etc. DPT will promptly notify COMPANY of
any such unforeseen circumstances before proceeding at which time either COMPANY or DPT may terminate the project or mutually agree to amend or 

  
 23 

 completely revise the Project Protocol. In the case where the project is terminated or
revised, COMPANY will be obligated to pay for all of the work performed by DPT up to that point. 
  

	 	(c)	Costs 

 Material
costs involved will be billed to COMPANY at DPT’s cost [...***...] for administration and carrying costs. The foregoing development costs shall be paid to DPT in accordance with DPT’s standard invoicing procedures regardless of
whether DPT is able to accomplish the results which COMPANY requested. All invoices shall be paid by COMPANY in accordance with paragraph 2.7 above. On or before sixty (60) days of the development of a finished product prototype (which shall
include final primary container selection filled with Research Product), DPT will provide an estimate of the Manufacturing Fee. DPT may also provide an estimate of the Materials Fee, should specifications be known for these items at such time. The
estimated Manufacturing Fee shall automatically be adjusted annually based upon CPI adjustments pending commencement of Production. 
  

	 	(d)	Obsolete Inventory 

Any COMPANY-specific inventory including, but not limited to, materials, bulk Research Product, waste by-products, testing supplies,
stability samples, work-in-process, and finished goods rendered obsolete at the conclusion, revision or termination of the development project shall be shipped to COMPANY or, at DPT election destroyed by DPT. COMPANY shall bear one hundred percent
(100%) of all destruction costs related to said obsolete inventory. The destruction shall be in accordance with all applicable laws and regulations and COMPANY shall indemnify DPT for any liability, costs or expenses, including attorney’s
fees and court costs, relating to COMPANY’s failure to dispose of such inventory in accordance with such laws and regulations. COMPANY shall also provide DPT with all manifests and other applicable evidence of proper destruction as may be
requested by DPT or required by applicable law. DPT shall notify COMPANY of its intention to dispose of inventory. If DPT does not receive disposition instructions from COMPANY within ninety (90) days from date of obsolescence, obsolete
inventory remaining at DPT’s facilities shall be subject to storage fees. 

  

							
		  	 	24	  	  	***Confidential Treatment Requested

 XI – INDEMNIFICATION 

 

	11.1	Indemnification by DPT 

Subject to paragraph 6.6 above, DPT will indemnify and hold COMPANY harmless against any and all liability, damage, loss, cost, or expense
(including reasonable attorney’s fees) resulting from any third party claims made or suits brought against COMPANY which arise from DPT’s breach of its warranties set forth in Section VI hereof, up to the amount of insurance coverage as
provided for herein. 
  

	11.2	Insurance by DPT 

 While
this Agreement is in full force and effect, DPT shall furnish COMPANY with evidence of Commercial General Liability insurance (including endorsements for Products and Contractual Liability) coverage affording a minimum amount of [...***...]
per occurrence combined single limit, bodily injury/property damage and [...***...] aggregate liability limits. Such evidence of insurance coverage can be in the form of the original policy or a Certificate of Insurance which shall name the
COMPANY as an additional insured and provided that DPT has assumed the liability as provided for herein. 
  

	11.3	Indemnification by COMPANY 

COMPANY will indemnify and hold DPT harmless against any and all liability, damage, loss, cost or expense (including reasonable
attorney’s fees) resulting from any third party claims made or suits brought against DPT which are related to the breach of any of COMPANY’s warranties provided for herein or which arise out of the promotion, distribution, use, testing or
sales of Products, including, without limitation, any claims, express, implied or statutory, made as to the efficacy, safety, or use to be made of Products, and claims made by reason of any Product Labeling or any Packaging containing Product
(provided such packaging and Labeling was purchased by DPT as provided in paragraph 2.2 (c) hereof), unless such liability, damage, loss or expense is caused by the breach of DPT’s warranties under Section VI hereof. 

 

	11.4	Insurance by COMPANY 

While this Agreement is in full force and effect, COMPANY shall furnish DPT with evidence of Commercial General Liability insurance
(including endorsements for Products and Contractual Liability) coverage affording a minimum amount of [...***...] per occurrence combined single limit, bodily 

  

							
		  	 	25	  	  	***Confidential Treatment Requested

 
injury/property damage and [...***...] aggregate liability limits. Such evidence of insurance coverage can be in the form of the original policy or a Certificate of Insurance which shall
name DPT as an additional insured and provide that COMPANY has assumed the liability as provided for herein. 
  

	11.5	Stacking of Insurance 

Neither COMPANY nor DPT intend for their respective insurance policies to stack on top of each other. To that end, both parties agree that
if a loss is incurred, for which DPT has an obligation under Section 11.1 to indemnify COMPANY hereunder, DPT’s policies will be triggered and DPT will defend COMPANY under the additional insured endorsement. Furthermore, if a loss is
incurred for which Company has an obligation under Section 11.3 to indemnify DPT hereunder, then COMPANY’s policies will be triggered and COMPANY will defend DPT under the additional insured endorsement. 

 

	11.6	Patent and Other Intellectual Property Rights 

  

	 	(a)	Warranty by COMPANY 

COMPANY warrants that use of Products or sales of Products will not infringe any patent or other proprietary rights and that COMPANY will
indemnify, defend and hold DPT harmless from any damage, judgment, loss, cost or other reasonable expense (including reasonable attorney’s fees) arising from claims that Products or the use of the Product names and any other trademarks, trade
names, or trade dress used by COMPANY in connection with Products infringes patent or other proprietary rights of a third party. 
  

	 	(b)	Warranty by DPT 

DPT shall indemnify and hold COMPANY harmless from all costs, damages and expense (including reasonable attorney’s fees) arising out
of any suit or action brought against COMPANY based upon a claim that any process or technical data furnished or utilized by DPT infringes any patent or other proprietary rights. 

  

							
		  	 	26	  	  	***Confidential Treatment Requested

	11.7	Conditions of Indemnification 

 If either party expects to seek indemnification from the other under paragraphs 11.1 or 11.3 hereof, it shall promptly give notice to the other party of any such claim or suit threatened, made or filed
against it which forms the basis for such claim of indemnification and shall cooperate fully with the other party in the defense of all such claims or suits. No settlement or compromise shall be binding on a party hereto without its prior written
consent. 
 XII - GENERAL PROVISIONS 

 

	12.1	Notices 

 Any notices
permitted or required by this Agreement shall be sent by certified or registered mail with a copy by fax and shall be effective the earlier of the date received or three (3) days after deposit in the U.S. mail, if sent and addressed as follows
or to such other address as may be designated by either party in writing: 
  

			
	If to DPT:	  	 DPT Lakewood, LLC
 c/o: DPT
Laboratories, Ltd.
 Attention: President

318 McCullough Ave.
 San Antonio, Texas
78215
 Fax: (210) 227-6132
 with a
copy to the General Counsel’s Office

		
	If to COMPANY:	  	 Insys Therapeutics
 10220 South
51st Street, Suite 2

Phoenix, AZ 85044
 Attention:
President
 Fax: (602) 910-2627

with a copy to the General Counsel’s Office

  

	12.2	Entire Agreement; Amendment 

 The parties hereto acknowledge that this document sets forth the entire agreement and understanding of the parties and supersedes all prior written or oral agreements or understandings with respect to the
subject matter hereof, and shall supersede any conflicting portions of DPT’s quotation, acknowledgment and invoice forms and COMPANY’s Purchase Order and other written forms. No modification of any of the terms of this

  
 27 

 
Agreement, or any amendments thereto, shall be deemed to be valid unless in writing and signed by the party against whom enforcement is sought. No course of dealing or usage of trade shall be
used to modify the terms and conditions herein. 
  

	12.3	Waiver 

 No waiver by
either party of any default shall be effective unless in writing, nor shall any such waiver operate as a waiver of any other default or of the same default on a future occasion. 

 

	12.4	Obligations to Third Parties 

 Each party warrants and represents that proceeding herein is not inconsistent with any contractual obligations, express or implied, undertaken with any third party. 

 

	12.5	Assignment 

 This
Agreement shall be binding upon and inure to the benefit of the successors or permitted assigns of each of the parties and may not be assigned or transferred by either party without the prior written consent of the other, which consent will not be
unreasonably withheld. No such assignment shall release the original party hereto from its duties and obligations under this Agreement. 
  

	12.6	Governing Law and Arbitration 

  

	 	(a)	Governing Law 

 The
validity, interpretation and effect of this Agreement shall be governed by and construed under the substantive laws of the State of New Jersey, excluding any conflicts of law provisions contained therein. 

 

	 	(b)	Arbitration 

  

	 	(i)	 ANY DISPUTE, CLAIM OR CONTROVERSY ARISING FROM OR RELATED IN ANY WAY TO THIS AGREEMENT OR THE INTERPRETATION, APPLICATION, BREACH, TERMINATION OR
VALIDITY THEREOF, INCLUDING ANY CLAIM OF INDUCEMENT OF THIS AGREEMENT BY FRAUD OR OTHERWISE, WILL BE SUBMITTED FOR RESOLUTION TO ARBITRATION PURSUANT TO THE 

  
 28 

	 	 
COMMERCIAL ARBITRATION RULES THEN PERTAINING OF THE CENTER FOR PUBLIC RESOURCES (“CPR”), EXCEPT WHERE THOSE RULES CONFLICT WITH THESE PROVISIONS, IN WHICH CASE THESE PROVISIONS
CONTROL. SUCH ARBITRATION SHALL BE HELD IN (I) COMPANY’S HOME COUNTY, IF THE DEMAND FOR ARBITRATION IS INITIATED BY DPT OR (II) OCEAN COUNTY, NEW JERSEY, IF THE DEMAND FOR ARBITRATION IS INITIATED BY COMPANY.

  

	 	(ii)	The panel shall consist of three arbitrators chosen from the CPR Panels of Distinguished Neutrals each of whom is a lawyer specializing in business litigation with at
least 15 years experience with a law firm of over 25 lawyers or was a judge of a court of general jurisdiction. In the event the aggregate damages sought by the claimant are stated to be less than $5 million, and the aggregate damages sought by the
counterclaimant are stated to be less than $5 million, and neither side seeks equitable relief, then a single arbitrator shall be chosen, having the same qualifications and experience specified above. 

 

	 	(iii)	 The parties agree to cooperate (1) to obtain selection of the arbitrator(s) within 30 days of initiation of the arbitration, (2) to meet with
the arbitrator(s) within 30 days of selection and (3) to agree at that meeting or before upon procedures for discovery and as to the conduct of the hearing which will result in the hearing being concluded within no more than 9 months after
selection of the arbitrator(s) and in the award being rendered within 60 days of the conclusion of the hearings, or of any post-hearing briefing, which briefing will be completed by both sides within 20 days after the conclusion of the hearings. In
the event no such agreement is reached, the CPR will select arbitrator(s), allowing appropriate strikes for reasons of conflict or other cause and three peremptory challenges for each side. The arbitrator(s) shall set a date for the hearing, commit
to the rendering of the award within 60 days of the conclusion of the evidence at the hearing, or of any post-hearing briefing (which briefing will be completed by both sides in no more than 20 days after the conclusion of the hearings), and provide
for discovery according to these time limits, giving recognition to the understanding of the parties hereto that they contemplate reasonable discovery, including document demands and depositions, but that such discovery be limited so that the time
limits specified herein may be met without undue difficulty. In no event will the arbitrator(s) allow either side to obtain more than a total of 40 hours of 

  
 29 

	 	 
deposition testimony from all witnesses, including both fact and expert witnesses. In the event multiple hearing days are required, they will be scheduled consecutively to the greatest extent
possible. 

  

	 	(iv)	The arbitrator(s) shall render an opinion setting forth findings of fact and conclusions of law with the reasons therefor stated. A transcript of the evidence adduced
at the hearing shall be made and shall, upon request, be made available to either party. 

  

	 	(v)	To the extent possible, the arbitration hearings and award will be maintained in confidence. 

 

	 	(vi)	Any court of competent jurisdiction may enter judgment upon any award. In the event the panel’s award exceeds $5 million in monetary damages or includes or
consists of equitable relief, then the court shall vacate, modify or correct any award where the arbitrators’ findings of fact are clearly erroneous, and/or where the arbitrators’ conclusions of law are erroneous; in other words, it will
undertake the same review as if it were a federal appellate court reviewing a district court’s findings of fact and conclusions of law rendered after a bench trial. An award for less than $5 million in damages and not including equitable relief
may be vacated, modified or corrected only upon the grounds specified in the Federal Arbitration Act. 

  

	 	(vii)	Each party has the right before or during the arbitration to seek and obtain from the appropriate court provisional remedies such as attachment, preliminary injunction,
replevin, etc. to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration. 

  

	 	(viii)	EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. 

  

	 	(c)	Mediation 

  

	 	(i)	 ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF OR RELATED TO THIS AGREEMENT, OR THE INTERPRETATION, APPLICATION, BREACH, TERMINATION OR VALIDITY
THEREOF, INCLUDING ANY CLAIM OF INDUCEMENT BY FRAUD OR OTHERWISE, WHICH CLAIM WOULD, BUT FOR THIS PROVISION, BE SUBMITTED TO ARBITRATION SHALL, BEFORE 

  
 30 

	 	 
SUBMISSION TO ARBITRATION, FIRST BE MEDIATED THROUGH NON-BINDING MEDIATION. SUCH MEDIATION SHALL BE HELD IN (I) COMPANY’S HOME COUNTY, IF THE DEMAND FOR MEDIATION IS INITIATED BY DPT OR
(II) OCEAN COUNTY, NEW JERSEY, IF THE DEMAND FOR MEDIATION IS INITIATED BY COMPANY AND SHALL BE ATTENDED BY A SENIOR EXECUTIVE WITH AUTHORITY TO RESOLVE THE DISPUTE FROM EACH OF THE OPERATING COMPANIES THAT ARE PARTIES.

  

	 	(ii)	After written notice of any dispute or controversy arising out of or related to the Agreement, or the interpretation, application, breach, termination or validity
thereof and Written Demand for Mediation (the “Written Demand for Mediation”), the parties shall promptly confer within thirty (30) days in an effort to select a mediator by mutual agreement. In the absence of such an agreement within
sixty (60) days of the date of the Written Demand for Mediation by either of the parties, the mediator shall be selected by the party making the demand for mediation. In the event that the party that has not made the Written Demand for
Mediation refuses to participate in the mediation process for any reason, or mediation is not scheduled within ninety (90) days of the Written Demand for Mediation for any reason, then the part that made the Written Demand for Mediation shall
have the absolute right to proceed to arbitration pursuant to paragraph 12.6(b) of this Agreement. 

  

	 	(iii)	The mediator shall confer with the parties to design procedures to conclude the mediation within no more than 45 days after initiation. Under no circumstances shall the
commencement of arbitration under Section 18(b) above be delayed more than 45 days by the mediation process specified herein. 

  

	 	(iv)	Each party agrees to toll all applicable statutes of limitation during the mediation process and not to use the period or pendency of the mediation to disadvantage the
other party procedurally or otherwise. No statements made by either side during the mediation may be used by the other during any subsequent arbitration. 

  

	 	(v)	Each party has the right to pursue provisional relief from any court, such as attachment, preliminary injunction, replevin, etc., to avoid irreparable harm, maintain
the status quo, or preserve the subject matter of the arbitration, even though mediation has not been commenced or completed 

  
 31 

	 	(d)	Costs 

 The costs
of arbitration and/or mediation, including reasonable attorney’s fees, shall be borne by the losing party. 
  

	12.7	Severability 

 In the
event that any term or provision of this Agreement shall violate any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or otherwise be unenforceable, such provision shall be ineffective to the extent of such
violation without invalidating any other provision hereof. 
  

	12.8	Headings, Interpretation 

The headings used in this Agreement are for convenience only and are not a part of this Agreement. 

 

	12.9	Counterparts 

 This
Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same original. 
  

	12.10 	Independent Contractor 

In performing its services hereunder, DPT shall act as an independent contractor. 

 

	12.11 	Export/Import Laws and Regulations 

 This Agreement is subject to any restrictions concerning the import or export of Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data) to
or from the United States as well as the laws and regulations of any other country involved in the import or export of such Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data).
COMPANY acknowledges that it shall be solely and exclusively responsible for the preparation of all import and export documentation and compliance with all import and export laws of the United States as well as the laws and regulations of any other
country involved in the import or export of such Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data); except as otherwise agreed by the parties in writing. COMPANY shall indemnify
and hold DPT, its officers, directors, 

  
 32 

 
employees, shareholders and affiliates harmless, from any and all claims, losses, liabilities, damages, fines, penalties, costs and expenses (including reasonable attorneys’ fees) arising
from, or related to, any breach by COMPANY of its obligations under this provision. COMPANY shall be the importer or exporter of record for all such import or export activities. COMPANY shall cooperate with DPT as reasonably necessary to permit DPT
to comply with the laws and regulations of the United States and any other country relating to the control of import or export of Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data).

 IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly authorized
officers as of the date first above written. 
  

									
	     INSYS THERAPEUTICS	 		 	     DPT LAKEWOOD, LLC
					
	By:	 	/s/ Michael Babich	 		 	By:	 	/s/ Paul Johnson
	Its:	 	President and CEO	 		 	Its:	 	 President & COO

  
 33 

 Schedule A 

[...***...] 

  

							
		  	 	34	  	  	***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]